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General Introduction 
 
Cannabis sativa L. is an annual dioecious plant, cultivated for over 4500 years. 
The medical use of Cannabis has a very long history: it has been known for 
centuries for its therapeutic properties. In 1964, a group of Israeli researchers 
isolated trans-Δ9-tetrahydrocannabinol (Δ9-THC), a terpenophenolic compound 
with psychoactive effects, considered the main constituent of Cannabis plant. 
Most of biological activities attributed to Cannabis have so far been linked to 
cannabinoids, and more specifically to THC. In the early 1990s the G-protein 
coupled cannabinoid receptors (CB) were discovered: cannabinoid receptor 
type 1 (CB1) and cannabinoid receptor type 2 (CB2).1 Their ligands are known 
as cannabinoids or endocannabinoids depending on whether they come from 
external or internal (endogenous) sources. Nowadays, it is known that many of 
the body functions are controlled by Cannabis-like substances in brain, immune 
system and other organs.2 Since the discovery of the cannabinoid receptors 
and their endogenous ligands, numerous studies focused on the 
endocannabinoid system are carried out. Clinical trials into Cannabis, pure 
cannabinoids and synthetic analogues have demonstrated some effectiveness 
as analgesics for chronic neuropathic pain, appetite stimulants’ for cancer or 
AIDS patients, and multiple sclerosis. The increased medical interest in these 
substances has caused the development of various Cannabis-based medicines.3  
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The Botany of Cannabis 
Cannabis sativa L. (Figure 1) is an annual, usually dioecious, more rarely 
monoecious, wind-pollinated herb, with male and female flowers developing on 
separate plants. It propagates from seed, grows vigorously in open sunny 
environments with well-drained soils, and has an abundant need for nutrients and 
water. It can reach up to 5 m in height in a 4-6 month growing seasons. 
 
 
Figure 1. Illustration of Cannabis sativa L. (“Flora von Deutschland, Österreich und der Schweiz”, 
Otto Wilhelm Thomè).  
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The sexes of Cannabis are anatomically indistinguishable before they start 
flowering, but after that, the development of male and female plants varies 
greatly. Shorter days, or more accurately longer nights, induce the plant to start 
flowering: the female plant produces several crowded clusters of individual flowers 
(flower tops). The male plants finish shedding their pollen and die before the seeds 
in the female plants ripen. 
According to current botanical classification, Cannabis belongs to the family of 
Cannabinaceae (also Cannabaceae or Cannabidaceae).2 
 
    Table 1   Current systematic classification of Cannabis2 
Domain Eukaryota 
Kingdom Plantae 
Superdivision Spermatophyta 
Division Angiosperms 
Class Dicotyledon 
Subclass Urticales 
Family Cannabinaceae 
Genus Cannabis 
Species Sativa L. 
Varieties Indica, vulgaris 
 
 
The upper leaves, unfertilized flower heads, and flower bracts of the female plant 
are the primary source of cannabinoids in Cannabis. The cannabinoids are 
enclosed in tiny glandular trichomes found on bracts and floral leaves and 
unstalked, glandular trichomes found on vegetative leaves and pistillate (flower) 
bracts and produce the sticky resin containing cannabinoids and terpenes.4  
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Chemical Constituents of Cannabis 
With currently 538 known constituents, Cannabis is one of the chemically best-
studied plants. But because most of these constituents have not yet been properly 
characterized for biological activity, the Cannabis plant could be called a 
“neglected pharmacological treasure trove”. 
The most important classes of compounds are listed in Table 2. 
 
     Table 2   An overview of compounds identified in Cannabis2 
Compound class Compounds identified 
Terpenoids >120 
Cannabinoids >70 
Hydrocarbons 50 
Sugars and related compounds 34 
Nitrogenous compounds 27 
Noncannabinoid phenols 25 
Flavoniods 23 
Fatty acids 22 
Simple acids 21 
Amino acids 18 
Simple ketones 13 
Simple esters and lactones 13 
Simple aldehydes 12 
Proteins, glycoproteins and enzymes 11 
Steroids 11 
Elements 9 
Simple alcohols 7 
Pigments 2 
Vitamin  1 (vitamin K) 
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The most interesting among these constituents are those found in the secretions 
of the head cells of glandular hairs (trichomes) distributed across the surface of the 
Cannabis plant. Although trichomes can be found all over the male and female 
plants, they are particularly concentrated on the bracts that support the female 
inflorescence. Solitary resin glands, consisting of one or two dozen cells, most 
often form at the tips of slender trichome stalks that form as extensions of the 
plant surface. The resin excreted by the glands contains a variety of constituents, 
any of which might play a role in the biological activities of the Cannabis plant. 
Among these are terpenoids, flavonoids, and cannabinoids. Resin collects under a 
thin waxy membrane surrounding the secretory head cells. In these extracellular 
resin pockets, the secreted compounds are segregated from the secretory cells, 
protecting it from both oxidative degradation and enzymatic change.2  
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Cannabinoids 
Cannabinoids are considered to be the main biologically active constituents of the 
Cannabis plant, and they can be found nowhere else in nature. The majority of 
biological activities attributed to Cannabis have so far been linked to cannabinoids, 
and more specifically to THC. The naturally occurring cannabinoids form a complex 
group of closely related compounds of which currently 70 are known and well 
described. 
Until the 1980s, the term cannabinoids represented by definition the group of 
typical terpenophenolic C21 compounds present in C. sativa, their carboxylic acids, 
analogues and transformation products. A modern definition will put more 
emphasis on synthetic chemistry and on pharmacology, and would also include 
related structures or compounds that affect cannabinoid receptors. The term 
“cannabinoids” now represents the whole set of endogenous, natural, and 
synthetic ligands of the cannabinoid receptors, belonging to a wide variety of 
chemical families. 
Chemically, the cannabinoids belong to the terpenophenols, which are common in 
nature.2 The most important phytocannabinoid is Δ9-tetrahydrocannabinol (Δ9-
THC), a terpenophenolic compound with psychoactive effects, considered the 
main constituent of Cannabis plant (Figure 2). 
 
 
Figure 2. Δ9-tetrahydrocannabinol (Δ9-THC).  
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Biosynthesis of Cannabinoids 
In all biosynthetic pathways for cannabinoids that were postulated until 1964, 
cannabidiol (CBD) or cannabidiolic acid (CBDA) was regarded as the key 
intermediate, which was supposedly built from a monoterpene and olivetol or 
olivetolic acid (OA), respectively. However, Gaoni and Mechoulam showed that 
cannabigerol (CBG) is the common precursor of cannabinoids, biosynthesized 
through the condensation of geranyldiphosphate and olivetol or OA. Subsequently, 
they concluded that CBD, THC, and cannabinol (CBN) all derive from CBG and differ 
mainly in the way this precursor is cyclized. 
It is now known that cannabinoids are produced by the metabolism of the plant in 
the form of carboxylic acids, where the substituent at position 2 is a carboxyl 
moiety (–COOH). The first specific biosynthetic step is the condensation of geranyl 
pyrophosphate (GPP) with OA into cannabigerolic acid (CBGA), catalyzed by the 
prenylase enzyme geranyldiphosphate: olivetolate-geranyltransferase (GOT). 
Furthermore, biosynthetic pathways finally became clear by identification and 
subsequent cloning of the genes responsible for the conversion of CBGA to 
tetrahydrocannabinolic acid (THCA), CBDA, and cannabichromenic acid (CBCA), 
respectively. 
The terpenoid GPP is derived from the deoxyxylulose phosphate/methyl-erythritol 
phosphate (DOXP/MEP) pathway. Not much is known about the biosynthesis of OA 
yet, but it has been proposed that a polyketide synthase (PKS) could be involved 
(Figure 3).2  
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Figure 3. General overview of the biosynthesis of cannabinoids and putative routes.2  
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The Endocannabinoid System  
The endocannabinoid system is now known to be an ubiquitous neuromodulatory 
system with wide-ranging actions.2 
It consists of: 
- cannabinoid receptors; 
- endogenous cannabinoids (endocannabinoids); 
- synthetic and degrading enzymes.2, 5 
 
 
 
Figure 4. The Endocannabinoid System: a general overview (International PhD course “Science of 
Drug and Bioactive Substances”, Pisa, (2015), Dr. A. Chicca).  
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The Cannabinoid Receptors 
Devane et al. (1988) first demonstrated the existence of a G-protein-coupled 
cannabinoid receptor in rat brain that is activated by Δ9-THC and a gene encoding 
this protein was identified in 1990 by Matsuda et al. A second G-protein-coupled 
cannabinoid receptor, that shares sequence similarity with the brain 
cannabinoid receptor, was identified in immune cells in 1993 and with this 
discovery the brain receptor was named CB1 (cannabinoid receptor type 1) and 
the immune cell receptor was named CB2 (cannabinoid receptor type 2).6, 7, 8 
The human CB1 gene (Figure 5) is located on chromosome 6 at locus q14-q15. The 
472 amino acid residue CB1 receptor protein is encoded by a single exon with 5’ 
and 3’ untraslated regions (UTRs).8, 9 
 
 
 
Figure 5. Human CB1 cannabinoid receptor gene. The diagram shows the structure of the 
human CB1 gene, comprising three non-coding exons (Ex 1-3), one coding exon (Ex4) and 
three introns (In 1-3), and alternatively-spliced mRNA transcripts (CB1A, CB1B, CB1C, CB1D, 
CB1E) that have variable 5’ untraslated regions.8 
 
 
The human CB2 cannabinoid receptor gene is located on chromosome 1 at 
locus p36.11 and comprises an exon encoding the 360 amino acid residue 
receptor protein and a 5’ exon encoding an UTR.8, 9 
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The protein sequences of CB1 and CB2 share about 45% identity and 68% similarity 
for the transmembrane domains. 
Cannabinoid receptors belong to the large superfamily of receptors that couple to 
guanine-nucleotide binding proteins and thread through cell membranes seven 
times (heptahelical receptors). CB receptors contain a N-terminal extracellular 
domain that possesses glycosylation sites, a C-terminal intracellular domain 
coupled to a G-protein complex and 7 hydrophobic transmembrane segments 
connected by alternating extracellular and intracellular loops (Figure 6).10 
 
 
Figure 6. CB receptors belong to 7TM-GPCRs superfamily. 
 
The CB1 receptor is most clearly localized in the central nervous system (CNS), 
therefore it is often called the “central receptor”. This receptor is thought to be the 
most widely expressed G-protein-coupled receptor in the brain: a high density of 
CB1 receptor was found in the hippocampus, some olfactory regions, caudate, 
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putamen, accumbens nucleus (ventral striatum), the substantia nigra pars 
reticulata (SNr), globus pallidus, and the horizontal limb of the diagonal band. CB1 
receptor has been also identified in peripheral tissues such as cardiovascular and 
reproductive cells.2, 10 
In contrast to previously described predominant presynaptic localisation of CB1 
receptor in the brain, CB2 receptor is widely distributed in peripheral tissues and 
particularly in immune tissues. This receptor was detected also in both microglia 
and neurons in the CNS.9, 10 
Both cannabinoid receptors are coupled with Gi or Go protein, negatively to 
adenylyl cyclase and positively to mitogen-activated protein (MAP) kinase (Figure 
7). CB1 coupling to the G-protein signal transduction pathways in presynaptic 
nerve terminals transduces the cannabinoid stimulation of MAP kinase and 
inhibition of adenylyl cyclase, thus attenuating the production of cAMP. CB1 is also 
coupled to ion channels through Gi/o proteins, positively to A-type and inwardly 
rectifying potassium channels, and negatively to N-type and P/Q-type calcium 
channels and to D-type potassium channels. 
 
 
Figure 7. CB receptors: signal transduction (Boiser B, et al., “Biochem. Pharmacol.”, 2010). 
 
14 
 
Due to the decrease of cAMP accumulation, cAMP-dependent protein kinase (PKA) 
is inhibited by CB1 activation. In the absence of cannabinoids, PKA phosphorylates 
the potassium channel protein, thereby exerting decreased outward potassium 
current. In the presence of cannabinoids, the phosphorylation of the channel by 
PKA is reduced, which leads to an enhanced outward potassium current. Based on 
these findings, it has been suggested that cannabinoids play a role in regulating 
neurotransmitter releases: inhibition of presynaptic calcium channels reduces 
neurotransmitter release from CB1-expressing presynaptic terminals. 
Presynaptic inhibition of neurotransmitter release by cannabinoids may turn out to 
be a key neuronal effect of cannabinoids. 
It has been proposed that endocannabinoids acting at presynaptic CB1 receptor 
are responsible for depolarization-induced suppression of excitation or inhibition 
via the inhibition of Ca2+ channel influx. 
Endocannabinoids serve as extracellular retrograde messengers, with 
characteristics very different from other neurotransmitters: they are released by 
depolarized postsynaptic neurons and may act on the presynaptic CB1 receptor. 
The resulting inhibition of presynaptic Ca2+ channels may serve to limit either 
excitatory or inhibitory outputs to the postsynaptic neuron from particular 
terminal: activation of the cannabinoid receptor temporarily reduces the amount 
of conventional neurotransmitter released (negative feedback mechanism to 
regulate transmitter release at GABAergic, glutamatergic, and dopaminergic 
synapses). The ultimate effect of this process depends on the nature of the 
transmitter that is controlled, which itself depends on the function of the tissue 
where the cannabinoid receptors are expressed (Figure 8).2, 11, 12 
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Figure 8. CB1 activation in the brain: depolarization-induced suppression of excitation or inhibition 
(Brock T., “Cayman Chemicals”). 
 
 
The CB2 receptor is also coupled to Gi/o proteins and thereby negatively coupled to 
adenylyl cyclase and the cAMP pathway in various types of cells, and it stimulates 
mitogen-activated protein kinase (MAPK) cascades. CB2 receptor is located 
principally in immune cells, among them leucocytes and those of the spleen and 
tonsils: one of the functions of these receptors in the immune system is 
modulation of cytokine release. Activation of B- and T-cell CB2 receptor by 
cannabinoids leads to inhibition of adenylyl cyclase and to a reduced response to 
immune challenge.10 
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Reward circuitry 
The psychoactive properties of marijuana are mediated by the active constituent, 
Δ9-THC, interacting primarily with CB1 cannabinoid receptor in a large number of 
brain areas. However, it is the activation of this receptor located within the central 
brain reward circuits that is thought to play an important role in sustaining the 
self-administration of marijuana in humans, and in mediating the anxiolytic and 
pleasurable effects of the drug. 
The reward circuitry of the brain consists of neurons that synaptically connect a 
wide variety of nuclei. Of these brain regions, the ventral tegmental area (VTA) and 
the nucleus accumbens (NAc) play central roles in the processing of rewarding 
environmental stimuli and in drug addiction.13 
The rewarding properties of addictive drugs are thought to be mediated by their 
action on the mesolimbic dopamine system. This dopamine system originates in 
the ventral tegmental area and projects to the ventral striatum, which 
predominantly comprises the nucleus accumbens. Addictive drugs probably induce 
their rewarding effects by enhancement of synaptic dopamine levels in the ventral 
striatum.14 
The dopaminergic neurons in this circuit do not have CB1 receptor, but they are 
normally inhibited by GABAergic neurons that do have them. The axon terminals of 
two GABA containing neurones in the ventral tegmental area might be targets for 
the action of Δ9-THC. Both neurones tonically inhibit dopamine-containing 
neurones and inhibition of GABA release via presynaptic cannabinoid receptors 
would be expected to increase the activity of the dopaminergic fibre tract (Figure 
9).15 
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Figure 9. Effect of Δ9-THC on the mesolimbic reward system. (a) The dopaminergic fibre tract 
(blue) projecting from the ventral tegmental area to the nucleus accumbens shell region is under 
the inhibitory control of a GABA-containing interneurone (red) in the ventral tegmental area and a 
long-loop GABA-containing feedback neurone (red) projecting from the nucleus accumbens to the 
ventral tegmental area. (b) Many drugs of abuse increase dopamine release in the nucleus 
accumbens. The facilitatory effect of Δ9-THC on dopamine release might theoretically be explained 
by a direct effect on the dopamine-containing neurone (extremely unlikely) or by activation of 
presynaptic inhibitory cannabinoid CB1 receptors on the two GABA-containing neurones (more 
likely). A more plausible explanation would be that Δ9-THC activates presynaptic inhibitory CB1 
receptors on the glutamatergic afferents (green) to the long-loop GABA-containing feedback 
neurone.15 
 
 
In 2009 Bossong et al. demonstrated the THC-induced dopamine release in the 
human striatum: cannabinoids induce elevated striatal dopamine levels and these 
effects are dependent on the activation of cannabinoid CB1 receptor. This effect 
may be explained by the indirect effects of THC on striatal dopamine levels 
through cannabinoid CB1 receptor on glutamate and GABA neurons in the nucleus 
accumbens and the ventral tegmental area.14  
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Endogenous Cannabinoids 
Endocannabinoids are so named because they were first identified as activating 
the same receptors as cannabinoids, the primary psychoactive components of 
Cannabis.2, 5, 10 
The discovery of the presence of receptors capable of binding THC, led the 
researchers to hypothesize the existence of an endogenous ligand able to bind 
cannabinoid receptors. In fact, in 1992, Devane et al. isolated, from the brain 
tissue of pigs, the first endogenous ligand capable of a selective binding to 
cannabinoid receptor (CB1): N-arachidonoylethanolamine or anandamide 
(AEA). Chemically, AEA is an amide resulting from the condensation between 
arachidonic acid and ethanolamine (Figure 10). 
 
 
Figure 10. Structure of anandamide (AEA). 
 
 
A few years later, another related ligand, belonging to the class of 
monoacylglycerol, was discovered from canine gut: 2-arachidonylglycerol (2-
AG) (Figure 11). This lipid was present at a concentration 100-200 times higher 
than AEA and had the same effects of THC. 2-AG was proposed as the main CB2 
ligand. Later it was discovered that while AEA preferentially activated the CB1, 
2-AG could activate indifferently both types of cannabinoid receptors. 
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Figure 11. Structure of 2-arachidonylglycerol (2-AG). 
 
Currently, several derivatives of fatty acid and analogues of AEA and 2-AG are 
known: N-arachidonoyl dopamine (NADA), 2-arachidonyl glyceryl ether 
(Noladin ether), able to bind both cannabinoid receptors, and virodhamine, 
with an antagonist activity towards CB1 receptor.1 
 
 
Synthetic pathway 
A feature that distinguishes endocannabinoids from many other neuromodulators 
is that they are not synthesised in advance and stored in vesicles. Rather, their 
precursors exist intracellularly in the plasma membrane of neurons as part of 
certain phospholipids and are cleaved by specific enzymes. This form of synthesis 
is often referred to as “on demand”: endocannabinoids are produced by distinct 
biochemical pathways involving phospholipases C and D, as well as other enzymes. 
These events are triggered by the enhancement of intracellular calcium 
concentrations that follow cell depolarization or the mobilization of intracellular 
calcium stores subsequent to the stimulation of protein-coupled receptors from 
the Gq/G11 family. Accordingly, the enzymes catalyzing anandamide and 2-AG are 
calcium-sensitive.2, 5, 10 
 
The mechanisms of anandamide biosynthesis in the nervous system are 
incompletely understood. The most accepted pathway for the synthesis of AEA 
involves the action of Ca2+-dependent N-acyltransferase (NAT) and a specific lipase 
called N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD). 
20 
 
NAT transfers the arachidonic acid from the phosphatidylcholine sn-1 position to 
the primary amine of phosphatidylethanolamine to form N-arachidonoyl 
phosphatidylethanolamine (NArPE). NAPE-PLD hydrolyzes NArPE, in presence of 
Ca2+, to release AEA and phosphatidic acid. 
Multiple mechanisms and putative anandamide biosynthetic enzymes have been 
suggested. A second synthetic pathway involves the hydrolysis of NArPE (produced 
by NAT) to phospho-AEA (p-AEA), catalyzed by phospholipase C (PLC). Afterwards, 
p-AEA is dephosphorylated to AEA (Figure 12A).1, 16 
2-AG is also synthesized “on demand” from membrane phospholipid precursors. 
2-AG is synthesized from arachidonoyl-containing diacylglycerol (DAG) species by 
sn-1-specific diacylglycerol lipase-α and -β (DAGLα and DAGLβ): 1-acyl-2-
arachidonylglycerol (DAG) is the first product of this synthetic pathway. 
DAG could be synthesized through two different reactions: one catalyzed by PLC, 
which operates on phosphatidylinositol, and the other by a phosphohydrolase, 
which hydrolyzes phosphatidic acid. Diacylglycerol lipase (DAGL) turns DAG into 2-
AG. PLC could also turn phosphatidylinositol (PI) into lyso-PI and it is transformed 
in 2-AG by a Ca2+-dependent PLC (Figure 12B).1, 16 
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Figure 12. (A) Anandamide biosynthesis (B) 2-AG biosynthesis.16 
 
 
 
Transport mechanism 
After formation, endocannabinoids are transported across the cell membrane to 
interact with their extracellular binding sites on cannabinoid receptors.2 
Endocannabinoids, because of their lipophilic nature, are able to cross the lipid 
bilayer. Nevertheless, researchers think about the existence of a specific carrier on 
the plasma membrane that internalizes endocannabinoids. Although this protein 
has not been identified yet, its activity has been widely featured in many neuronal 
and peripheral cells, in peripheral organs and central nervous system (CNS). 
It has been postulated the existence of specific membrane carrier of 
endocannabinoids: endocannabinoid membrane transporter (EMT). EMT let 
endocannabinoids to cross the plasma membrane. The diffusion occurs in both 
directions (in and out of the membrane) and does not depend on ATP hydrolysis.1  
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Degrading enzymes 
Endocannabinods’ biological action has a short life, depending on a deactivation 
process: reuptake, enzymatic hydrolysis and riesterification of products. 
In the nervous system, anandamide and 2-AG are degraded primarily by the serine 
hydrolase enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase 
(MAGL), respectively.16 
Anandamide is extremely unstable, and quickly hydrolysed by FAAH yielding 
ethanolamine and arachidonic acid (Figure 13). Two mechanisms for anandamide 
inactivation have been identified in the brain. The first is intracellular hydrolysis by 
FAAH.1, 10 
 
 
Figure 13. Anandamide degradation.1 
 
FAAH is both a serine hydrolase, an enzyme class that utilizes a nucleophilic serine 
for catalysis, and a member of the amidase signature enzyme family. FAAH is an 
~60 kDa integral membrane protein that is highly expressed in the mammalian 
brain where it localizes to intracellular membranes of postsynaptic somata and 
dendrites. It is a homodimeric enzyme that can accommodate its substrate into a 
complex architecture of the catalytic site, which is characterized by three binding 
AEA 
FAAH 
AA 
Ethanolamine 
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channels. Substrates are thought to reach the catalytic site via a membrane access 
(MA) channel where two charged residues (Asp403 and Arg486) may favour the 
entrance of the polar head groups of fatty acid molecules. The catalytic action of 
FAAH occurs in the core of the binding site where an unusual catalytic triad 
(Ser241–Ser217–Lys142) performs the hydrolysis of the substrate, while an oxyanion 
hole keeps the substrate properly oriented for hydrolysis. Tightly connected to the 
catalytic region, a cytosolic port (CP) allows the exit of the leaving group after 
substrate hydrolysis. A third acyl-chain binding (AB) cavity, adjacent to the MA 
channel, seems to contribute to the proper accommodation of the substrate 
during catalysis (Figure 14).16 
 
 
Figure 14. FAAH catalytic activity (Palermo G. et al., “J Chem Theory Comput”, 9, 2013, pp. 1202-
1213). 
 
After the discovery of 2-AG as a second endocannabinoid, its inactivation in the 
nervous system was hypothesized to proceed through monoacylglycerol lipase 
(MAGL), a soluble serine hydrolase that peripherally associates with cell 
membranes (inner plasma leaflet).16 In the CNS is highly expressed in the pre-
synaptic neurons (colocalized with CB1 receptor in the axon terminals), astrocytes 
and glial cells. In the periphery is abundantly expressed in many tissue and 
immune cells (low or negligible in macrophages).17 MAGL hydrolyzes the ester 
bond of 2-AG, releasing arachidonic acid and glycerol (Figure 15).1 
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Figure 15. 2-AG degradation.1 
 
There is evidence that, in addition to MAGL, the brain expresses other enzymes 
that can hydrolyze 2-AG: the postgenomic proteins α/β-hydrolase domain 
containing ABHD6 and ABHD12 that remain poorly characterized. 
ABHD6 is an integral membrane protein localizing to the post-synaptic neuronal 
membrane and in the glia. The active site is predicted to face the 
cytosol/intracellular membrane. In neurones ABHD6 localizes to sites of 2-AG 
generation, including post-synaptic dendrites of principal glutamatergic neurones 
as well as some GABAergic interneurones. 
ABHD12 is predicted to be an integral membrane protein highly expressed in 
microglia. ABHD12 transcripts are also found in related cell types (macrophages, 
osteoclasts) and this hydrolase is therefore potentially positioned to guard 2-AG-
CB receptor signaling in these cells. The active site is predicted to face the 
luminal/extracellular side.18, 19  
2-AG 
AA 
Glycerol 
MAGL 
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Therapeutic potential of Cannabinoids 
Cannabinoids are best known for their effects on CNS functions. 
They produce euphoria, alterations in cognition and analgesia, have 
anticonvulsivant properties and affect temperature regulation, sleep and appetite. 
However, cannabinoids also possess immunomodulatory activity and anti-
inflammatory properties. Many disease of the CNS including Alzheimer disease, 
Parkinson’s disease, AIDS dementia and mainly Multiple Sclerosis (MS) involve 
inflammation, and cause an upregulation of cytochines and other inflammatory 
mediators in the CNS. Therefore cannabinoids may be potential therapeutic agents 
in neurological diseases. 
 
 
Role of CB receptors in Neuroprotection 
Accumulated evidence has suggested a role of the CB receptors in 
neuroprotection. The blood-brain barrier (BBB) is an important brain structure that 
is essential for neuroprotection. A link between the CB receptors and the BBB is 
thus likely, but this possible connection has only recently gained attention. 
Cannabinoids and the BBB share the same mechanisms of neuroprotection and 
both protect against excitotoxicity (CB1), cell death (CB1), inflammation (CB2) and 
oxidative stress (possibly CB independent), all processes that also damage the BBB. 
The CB receptors were shown to improve BBB integrity, particularly by restoring 
the tightness of the tight junctions. Both CB receptors are able to restore the BBB 
and neuroprotection, but much uncertainty about the underlying signaling 
cascades still exists. 
The most extensively studied mechanism of neuroprotection includes the anti-
inflammatory effects of the CB2 receptor, in which CB2 protects the brain by 
preventing neuroinflammation. In contrast, the CB1 receptor has been implicated 
in protection against cell death induced by an overstimulation of excitatory 
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receptors and concurrent calcium release, also known as excitotoxicity (Figure 
16).20, 21 
 
Figure 16. The influence of the CB1 receptor on intracellular calcium levels and neurotransmitter 
release as is relevant in excitotoxicity.20 
 
 
 
Role of CB receptors in Neuropathogenesis 
The CB1 and CB2 have been implicated in a number of neuropathogenic processes. 
The cannabinoid receptor type that is linked to an inflammatory response within 
the CNS appears to be CB2. Microglia apparently act as the major expressers of 
this receptor during early stages of neuroinflammation. As resident macrophages 
in the CNS, they migrate and proliferate during and after injury and inflammation, 
phagocytose and process antigens, and once activated produce proinflammatory 
factors including the cytokines interleukin (IL)-1, IL-6, and tumor necrosis factor 
(TNF) α. Pro-inflammatory mediators released from microglia not only are 
exocytotoxic, but also can secondarily activate astrocytes leading to a further 
induction of the expression of inflammatory factors. 
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In vitro and in vivo studies have shown that cannabinoids can act on glia and 
neurons to inhibit the release of pro-inflammatory cytokines and enhance the 
release of anti-inflammatory factors such as the cytokines IL-4 and IL-10. These 
observations suggest that these cannabinoids, as lipophilic molecules, can readily 
access the CNS and have the potential to ablate a variety of neuropathological 
processes that are associated with proinflammatory states.22 
 
 
 
Multiple Sclerosis (MS) 
Multiple Sclerosis is a chronic disease of the CNS, where autoimmunity is thought 
to drive the development of inflammatory lesions that induce the primary 
demyelination, which results in the inhibition of normal neurotransmission.12 
This pathology causes muscle weakness, abnormal muscle spasms, change in 
sensation, difficulty in coordination and balance, cognitive impairment, 
problems with speech, swallowing and sight. The disease is characterized by 
degeneration of the myelin sheath that covers axons, in which T cells play a 
prominent role. The cells attack myelin with the resulting inflammatory process 
and so other immune cells are stimulated to produce soluble factors such as 
cytokines and antibodies. 
The inflammatory process results in breakdown of the BBB leading to swelling, 
activation of macrophages and further production of cytokines and “cytotoxic” 
proteins such as metalloproteinases. Remyelination may occur in the early 
phase of the disease and it could be an opportunity for healing, but the 
oligodendrocytes that originally formed the myelin sheath cannot completely 
rebuild the destroyed myelin.22 
CB1 and CB2 receptors expression is a specific markers of plaque cell subtypes 
in MS lesions. CB1 receptor is in fact expressed in cortical neurons, 
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oligodendrocytes, macrophages, and infiltrated T lymphocytes, whereas CB2 
receptor is present in astrocytes and in microglial cells. 
Several experimental models have shown that the activation of cannabinoid 
receptors in the inflammatory demyelinative process characterizing MS may 
cause a neuroprotective effect through a CB1 receptor-mediated inhibition of 
excitotoxicity and through a CB2 receptor-mediated inhibition of 
neuroinflammation. 
The treatment with CB-mimetic substances suppresses inflammatory responses 
in the CNS of EAE (Experimental Autoimmune Encephalomyelitis) animals and 
improves their neurological symptoms by inhibiting the expression of 
proinflammatory cytokines23, by reducing microglial activation, by abrogating 
major histocompatibility complex class II antigen expression, and by promoting 
remyelination (Figure 17). Treatment with drugs able to modulate the 
endocannabinoid tone has in fact exerted efficacy. However, the use of Cannabis 
derivatives in MS patients should be considered cautiously, whereas the strategies 
to modulate endogenous CB system could have particular therapeutic interest.24 
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Figure 17. The complex role of the cannabinoid system and possible therapeutic targets in MS-
induced inflammation. Cannabinoids may combat inflammation by modulating cytokines, 
inflammatory mediators, T cell proliferation and effector function, B cell antigen presentation and 
activation of microglia and astrocytes. Moreover, they may limit the ability of leukocytes to cross 
the BBB and enter the brain by inhibition of molecules implicated in leukocyte endothelium 
trafficking.20  
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Alzheimer’s disease (AD) 
AD is the most common chronic neurodegenerative disorder that causes senile 
dementia. The series of events that leads to AD is poorly understood and insights 
into its pathogenesis have been obtained primarily from assessment of human 
brain tissue at autopsy. Neurodegeneration in AD affects multiple 
neurotransmitter systems, including those of specific cholinergic, noradrenergic, 
serotonergeic, GABAergic, and glutamatergic neurons. 
The defining neuropathologic features of the disease are the presence of 
extracellular neuritic amyloid plaques and intracellular neurofibrillary tangles 
(NFTs) in the brain. The appearance of these stigmata is accompanied by synaptic 
and neuronal loss and gliosis in the cerebral cortex and the limbic system. The 
amyloid plaques consist of extracellular aggregates of amyloid β (Aβ) peptides that 
often are surrounded by activated microglia and astrocytes. The NFTs consist of 
intraneuronal aggregates of paired-helical filaments that usually are composed of 
hyperphosphorylated microtubule-associated protein tau. As neurodegeneration 
progresses there is accelerated neurofibrillary tangle formation, 
neuroinflammation, and neuronal loss. 
Alterations in components of the cannabinoid system have been observed in 
brains of Alzheimer’s patients, suggesting that this system contributes to, or is 
altered by, the disease (Figure 18). It was suggested that the losses in cannabinoid 
receptors, while related to generalized aging and/or the disease process, were not 
selectively associated with the pathology characteristic of AD. On the other hand, 
CB2 and FAAH have been reported to be selectively over-expressed in neuritic 
plaque-associated glia in AD brains. 
Intracerebroventricular administration of cannabinoid receptor agonist WIN55212-
2 prevented Aβ-induced activation of microglia, cognitive impairment, and loss of 
neuronal markers. In addition, treatment of microglia in vitro with CB receptor 
agonists HU-210, WIN55212-2 and JWH-133 resulted in blockage of their activation 
by Aβ peptide and abrogated neurotoxicity mediated by these cells. These results 
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are consistent with those that indicated that WIN-55212-2 exerted anti-
inflammatory properties. It has been reported that stimulation of CB2 results in 
suppression of inflammatory mediators such as NO, cytokines, and chemokines 
that play a role in microglial cell-associated neuronal damage.22,25 
 
 
Figure 18. Summary of the main findings demonstrating beneficial effects of cannabinoid 
compounds in AD models.25 
 
 
 
Amyotrophic Lateral Sclerosis (ALS) 
ALS is a fatal neurodegenerative disease that primarily affects motor neurons in 
the spinal cord, brainstem, and motor cortex, leading to complete paralysis. It is 
characterized pathologically by progressive degeneration of cortical motor 
neurons (upper motor neurons) and clinically by muscle wasting, weakness, and 
spasticity.22, 24 
This adult-onset disease occurs in both sporadic and familial forms. The familial 
ALS (FALS) form is inherited as an autosomal dominant trait and accounts for 5% to 
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10% of cases of ALS. FALS has been linked to mutations in the superoxide 
dismutase 1 (SOD1) gene that codes for a zinc and copper binding enzyme which 
neutralizes supercharged oxygen molecule (superoxide radical) byproducts of 
normal cellular metabolism.22 
The pathogenesis of ALS is incompletely understood but the degeneration of 
motor neurons has been related to several mechanisms, including neurofilament 
accumulation, excitotoxicity, oxidative stress, and neuroinflammation with 
microglial activation. All these pathological events are potentially modulated by 
endocannabinoids. 
It has been demonstrated that the levels of endocannabinoids are affected in 
experimental ALS. AEA and 2-AG are increased in the spinal cord of SOD1 
transgenic mice and up-regulated with disease progression. This up-regulation 
might represent a neuroprotective response, not robust enough to counteract 
disease progression. 
The ECS can interplay with the pathogenic events of ALS at different molecular and 
cellular levels. Neuroinflammation, microglial activation, oxidative stress, and 
excitotoxicity are involved in the pathophysiology of ALS and are potentially 
influenced by ECS. Disruption of extracellular glutamate homeostasis has been 
claimed to play a crucial role in ALS-associated excitotoxic damage, and activation 
of CB1 receptor protects against neuronal death induced by glutamate in other 
pathological conditions by reducing glutamate release from presynaptic terminals. 
Glutamate is known to induce the formation of reactive oxygen species, which 
inhibit glutamate uptake, thereby potentiating excitotoxic damage and oxidative 
stress in several pathological conditions including ALS. Microglial activation in the 
CNS is part of a neuroinflammatory reaction with deleterious effects on 
surrounding neurons. Endocannabinoids have been shown to reduce microglial 
activation as well as the expression and release of proinflammatory cytokines from 
microglia via CB2 receptor, providing a plausible explanation for their protective 
action in ALS. 
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CB2 receptor agonists or CB1 receptor antagonists should be identified as potential 
therapeutic agents in ALS. Neuronal CB1 receptors and microglial CB2 receptors 
might be suitable pharmacological targets in the early and late phases of ALS, 
respectively.24 
 
 
 
Pain 
Pain has a negative impact on the life quality in cancer patients. Almost half of all 
patients with cancer experience moderate to severe pain, and this increases in 
patients with metastatic or advanced stages of cancer. Cancer pain is often treated 
with oppioid drugs (codeine, morphine, and/or their synthetic analogues); 
however, these drugs have dose-limiting side-effects. The use of cannabinoids to 
treat cancer pain may provide a novel therapeutic approach, because they have 
the capability to inhibit pain transmission. 
The manifestation of pain and its modulation is mediated by ascending and 
descending pathways. The descending pathways modulate neuronal activity in the 
ascending pathways, and can modulate effects on pain sensation. The midbrain 
periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) are the most 
studied regions and represent a significant system that contributes to pain 
modulation. The PAG projects to the RVM, which in turn sends its output to dorsal 
horn laminae, which are important in nociceptive function. The PAG/RVM system 
exerts bidirectional control over nociceptive processing and it is recognized as the 
central site of action of analgesic agents including cannabinoids.26 
The components of the endocannabinoid system are found in regions involved in 
the transmission and modulation of nociceptive signaling26: CB1 receptors have 
shown particularly high levels in cells of the midbrain periaqueductal grey matter 
(PAG), and in the substantia gelatinosa of the spinal cord (receiving nociceptive 
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input from primary afferent neurons), which are key sites for modulating 
nociceptive information.27 
Cannabinoid receptor agonists have long been known to exhibit antinociceptive 
activity in animal models of acute pain through the activation of CB1 receptors: 
they have greater potency in suppressing responses to noxious pressure or 
thermal stimuli.26, 28 Recent experiments have demonstred that CB2 receptor-
selective ligands are more active in animal models with hyperalgesia. 
Health Canada approved Sativex in 2007, with conditions, as adjunctive analgesic 
treatment in adult patients with advanced cancer who experience moderate to 
severe pain during the highest tolerated dose of strong opioid therapy for 
persistent background pain. 
 
 
 
Cancer 
Cancer is a disease characterized by uncontrolled division of cells and their ability 
to spread. This unregulated growth is caused by damage to DNA, resulting in 
mutations, defects in cell cycle, and apoptotic machinery. Thus, agents that can 
modulate apoptosis to maintain steady-state cell population by affecting one or 
more signaling intermediates leading to induction of apoptosis can be useful for 
targeted therapy of cancer. 
A significant advancement in cannabinoid use in cancer treatment came through 
the discovery of a potential utility of these compounds for targeting and killing 
tumors. In subsequent studies, molecular mechanisms for these effects were 
analyzed, and it was found that cannabinoids inhibited tumor cell growth and 
induced apoptosis by modulating different cell signaling pathways in gliomas29 and 
lymphomas, prostate, breast, lung, skin, and pancreatic cancer cells. 
The block of the G1-S transition was ascribed to the inhibition of adenylyl cyclise 
and, consequently of cAMP-protein kinase A pathway and to the activation of 
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MAPK. Cannabinoids prevented the inhibition of RAF1 (caused by protein kinase A-
induced Raf phosphorylation) and induced prolonged activation of the RAF1-MEK-
ERK signaling cascade. Moreover, cannabinoids induce de novo synthesis of 
ceramides, a family of lipid molecules composed of sphingosine and a fatty acid, 
found in the cell membrane. Synthesis of ceramide occurs via activation of the 
enzyme ceramide synthase and leads to downstream activation of an extracellular 
regulated kinase (ERK) signaling cascade. This process results in cell cycle arrest 
and apoptosis. Activation of either CB1 or CB2 receptors triggers the ceramide-ERK 
signaling pathway to promote apoptosis. The increase in ceramide can also 
activate the p38 mitogen-activated protein kinase (p38MAPK) pathway, which can 
lead to apoptosis through multiple mechanisms. The over activation of ERK also 
promotes the induction of cyclin kinase inhibitor (p27/KIP1) which modulates 
regulatory molecules of the cell cycle (cyclins, cdks). Cell cycle arrest involves the 
up-regulation of the p53 protein which will differentially alter levels of pro- and 
anti-apoptotic proteins (i.e. increase the levels of the pro-apoptotic protein Bax 
and lower the levels of the anti-apoptotic protein Bcl2) which ultimately leads to 
activation of caspases that play an essential role in triggering apoptosis. 
The diversified effects of cannabinoids in modulating cell signaling pathways are 
depicted in Figure 19.30, 31 
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Figure 19. Schematic representation of signaling pathways associated with cannabinoid receptor 
activation induced by its agonists.30 
 
 
Levels of endocannabinoids and their receptors are increased in cancer, a situation 
that frequently correlates with tumor aggressiveness. Accordingly, anandamide 
and 2-AG have been shown to be over-expressed in several types of tumors 
including glioblastoma multiforme, meningioma, pituitary adenoma, prostate and 
colon carcinoma and endometrial sarcoma. 
Many different reports have shown that cannabinoid receptor agonists (derived 
from the plant, like THC, endogenous like 2-AG and anandamide or synthetic - with 
similar or different affinity for CB1 and CB2 receptors like WIN 55,2121-2 or JWH-
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133) exert antitumor effects in experimental models of cancer supporting that 
pharmacological stimulation of CB receptors is antitumorigenic. Cannabinoid 
treatment promotes cancer cell death, impair tumor angiogenesis and block 
invasion and metastasis. The mechanism of cannabinoid anticancer action relies, at 
least largely, on the ability of these agents to stimulate autophagy-mediated 
apoptotic cancer cell death: autophagy is considered primarily a cytoprotective 
mechanism. 
Cannabinoids have shown to normalize tumor vasculature. These effects seem to 
rely on the ability of cannabinoids to inhibit the stimulation of the vascular 
endothelial growth factor (VEGF) pathway. Thus, various components of the VEGF-
activated pathway have been shown to be down-regulated in response to 
treatment with cannabinoids in different cancer types. Cannabinoid receptor 
activation inhibits migration and proliferation and induces apoptosis in vascular 
endothelial cells which contribute to the antiangiogenic effect of cannabinoids. In 
addition, cannabinoids have been shown to reduce the formation of distant tumor 
masses in animal models of spontaneous and induced metastasis.30, 31, 32  
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Cannabinoid receptor ligands 
All the active compounds targeting the CB1 or CB2 receptor are classified into 
cannabinoids. The compounds could be classified as agonist, antagonist, and 
inverse agonists according to their functionality. The agonists produce an increase 
in the basal level of signaling after binding to the receptors, while the inverse 
agonists downregulate the signaling. In addition, the antagonists could prevent the 
agonists or inverse agonists modulating the receptors. Traditionally, cannabinoids 
can be divided into five classes based on the chemical scaffold, including classical 
cannabinoids, non-cassical cannabinoids, aminoalkylindoles, diarylpyrazoles, and 
endocannabinoids (or eicosanoids).33 
 
 
Canabinoid receptor Agonists 
1. Classical Cannabinoids 
This group of cannabinoids consists of ABC-tricyclic dibenzopyran derivatives that 
are either compounds occurring naturally in the plant, C. sativa, or synthetic 
analogs of these compounds. The most investigated of the classical cannabinoids 
have been Δ9-THC, Δ8-THC, 11-hydroxyl-Δ8-THC-dimethylheptyl (HU-210) and 
desacetyl-L-nantradol (Figure 20). Of these, Δ9-THC is the main psychotropic 
constituent of Cannabis. Δ8-THC is also a psychotropic plant cannabinoid, whereas 
HU-210 and desacetyl-L-nantradol are synthetic cannabinoids. All these 
cannabinoids have been demonstrated to elicit cannabimimetic responses both in 
vivo and in vitro. 
Δ9-THC undergoes significant binding to cannabinoid receptors at submicromolar 
concentrations with similar affinities for CB1 and CB2 receptors. At CB1 receptor, it 
behaves as a partial agonist; at CB2 receptor is even less than its relative intrinsic 
activity. Δ8-THC has affinities for CB1 and CB2 receptors that are similar to those of 
Δ9-THC and behaves as a partial agonist at CB1 receptor. HU-210 is particularly 
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potent cannabinoid receptor agonist: its pharmacological effects in vivo are also 
exceptionally long lasting.34, 35 
 
 
 
 
Figure 20. Structures of synthetic classical cannabinoid receptor agonists. 
 
 
 
2. Non-classical Cannabinoids 
Researchers at Pfizer synthesized new analogs lacking the dihydropyran ring of 
THC. CP47497 represents the prototypical compound of this series of AC-
bicyclic and ACD-tricyclic cannabinoid analogs. Further developments have led 
to the bicyclic analog, CP55940 (Figure 21), which has become one of the 
major cannabinoid agonists. It binds to CB1 and CB2 receptor with similar 
affinity and displays high activity in vivo being 10 to 50 times more potent than 
Δ9-THC. CP55940 behaves as a full agonist for both receptor types.34, 35 
 
     Δ9-THC 
CB1/CB2 affinity = 0.4 – 1.4 
CB1 Ki ≈ 40 nM 
CB2 Ki ≈ 40 nM 
   Δ8-THC 
CB1 Ki ≈ 47.6 nM 
CB2 Ki ≈ 39.3 nM 
   HU-210 
CB1 Ki ≈ 0.73 nM 
CB2 Ki ≈ 0.22 nM 
      Desacetyl-L-nantradol 
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Figure 21. Structure of non-classical cannabinoid receptor agonist CP55940. 
 
 
 
3. Aminoalkylindoles 
Sterling Winthrop researchers reported a new family of aminoalkylindoles 
possessing cannabimimetic properties. This discovery resulted from the 
development of structurally constrained analogs of pravadoline, a series of 
compounds with reduced ability to behave as nonsteroidal anti-inflammatory 
agents that inhibit cyclooxygenase but increased ability to bind to the CB1 
receptor. R-(+)-WIN55212 (Figure 22) is the most highly studied compound of the 
series. It displays high affinity for both cannabinoid receptors, with moderate 
selectivity in favour of the CB2 receptor, and exhibits high relative intrinsic activity 
at both CB1 and CB2 receptors. In vivo, it produces the full spectrum of 
pharmacological effects of THC and substitutes totally for other cannabinoids in 
discriminative stimulus tests, whereas its S-(-)-enantiomer, WIN55212-3, lacks 
activity both in vivo and in vitro.34, 35 
 
      CP55940 
CB1/CB2 affinity = 0.4 – 5.6 
CB1 Ki ≈ 0.5-5 nM 
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Figure 22. Structure of aminoalkylindole cannabinoid receptor agonist R-(+)-WIN55212. 
 
 
 
4. Endocannabinoids (Eicosanoids) 
The prototypic member of the eicosanoid group of cannabinoid receptor agonists 
is anandamide, which belongs to the 20:4, n-6 series of fatty acid amides. 
Anandamide behaves as a partial agonist at CB1 receptors and exhibits less relative 
intrinsic activity at CB2 than CB1 receptors. 
2-arachidonylglycerol is an agonist for both CB1 and CB2 receptors and exhibits 
higher relative intrinsic activity than anandamide at both CB1 and CB2 receptors. 
Structural modification of the anandamide molecule has led to the development of 
the first generation of CB1-selective agonists. Notable examples are R-(+)-
methanandamide, arachidonyl-2’-chloroethylamide (ACEA)35, 
arachidonylcyclopropylamide (ACPA)35, and O-1812 (Figure 23).34 
 R-(+)-WIN55212 
CB1/CB2 affinity = 6.8 - 30 
CB1 Ki ≈ 1.9-123 nM 
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Figure 23. Structures of endocannabinoids and synthetic cannabinoid receptor agonists. 
 
 
 
Canabinoid receptor Antagonists/Inverse Agonists 
1. Diarylpyrazoles 
The prototypic members of this series of compounds are the Sanofi compounds 
SR141716A (Rimonabant, Acomplia®), a potent CB1-selective ligand, and 
SR144528, a potent CB2-selective ligand (Figure 24). These ligands readily prevent 
or reverse effects mediated respectively by CB1 and CB2 receptor agonists. 
Although these effects of the arylpyrazole antagonists may be attributable to the 
inhibition of endogenously produced agonists in the biological preparation, there is 
evidence that SR141716A and SR144528 can evoke inverse agonist responses. This 
      Anandamide       2-Arachidonylglycerol 
      R-(+)-Methanandamide       ACEA 
      ACPA 
      O-1812 
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notion rests on the ability of the CB1 and CB2 receptor to exhibit signal 
transduction activity in the absence of endogenous or exogenous agonists 
(constitutive activity). As such, arylpyrazoles can behave as “inverse agonists” to 
reduce the constitutive activity of these signal transduction pathways. In some 
experiments, SR141716A has been found to be more potent in blocking the actions 
of CB1 receptor agonists than in eliciting inverse cannabimimetic responses by 
itself.34, 35, 36 
 
 
Figure 24. Structures of cannabinoid receptor antagonists/inverse agonists. 
 
Two analogs of SR141716A that have also been used to block CB1 receptor-
mediated effects: AM25137 and AM28137 (Figure 25). AM281 has 350 times greater 
affinity for CB1 than CB2 receptor, and both analogs share the ability of 
SR141716A to attenuate responses to established cannabinoid receptor 
agonists.34, 35 
 
 
Figure 25. Structures of cannabinoid receptor antagonists/inverse agonists. 
      SR-141716A       SR-144528 
      AM-251       AM-281 
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As a therapeutic target, the endocannabinoid system has found to date modest 
success. However, a number of new findings, coupled with current efforts for 
cannabinoid-based drug development, point to a more successful future. The 
ubiquitous presence of the endocannabinoid system presents difficulties in 
targeting it for therapeutic gain. For this reason, it is important that indications for 
cannabinergic drug development be explored very thoughtfully. In this regard, a 
better understanding of cannabinoid receptor-related functional selectivity should 
assist in the development of drugs with safer pharmacological profiles and also 
identify additional therapeutic opportunities.37  
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Aim of the Thesis 
 
The endocannabinoid system is now known to be an ubiquitous neuromodulatory 
system with wide-ranging actions. It consists of endogenous cannabinoids 
(endocannabinoids), cannabinoid receptors and synthetic and degrading enzymes 
responsible for synthesis and degradation of endocannabinoids. 
Endocannabinoids (EC) are lipid messengers derivatives of integral components of 
the cellular membranes: anandamide and 2-arachidonylglycerol are the best 
characterized. Their levels are maintained mainly by two catabolic enzymes: the 
fatty acid amide hydrolase (FAAH) and the monoacylglycerol lipase (MAGL). 
Cannabinoid receptors 1 and 2 (CB1 and CB2) belong to the superfamily of G-
protein-coupled receptors. CB1 receptor is predominant in the central nervous 
system while CB2 receptor is located mainly in immune cells, such as 
macrophages, microglia, and B and T cells. As CB1 receptor mediates most, if not 
all, of the psychoactive effects of cannabinoids, CB2 receptor selective ligands are 
attractive as therapeutics because they would presumably lack this psychoactivity. 
Therefore, therapeutic strategies might include the use of cannabinoid receptor 
agonists and/or antagonists, but also the blockage of hydrolytic enzymes 
degrading ECs, the inhibition of EC transporters (EMT) and the inhibition of EC 
uptake. However, the current comprehension of the complexity of the 
endocannabinoid system seems to indicate a need of multitarget drugs, which 
exert their pro-cannabinoid activities by means of more than one mechanism of 
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action. In fact, these molecules could offer the advantage of modulating the ECS in 
a safer and more therapeutically efficacious way. 
The growing interest in the endocannabinoid system has led several research 
groups to design and develop new selective ligands that could have a target in the 
ECS, avoiding the psychoactive effects. 
 
In a previous research program aimed at obtaining CB2 receptor selective ligands, 
a series of 2-oxo-1,2-dihydropyridine-3-carboxamide derivatives with general 
structures A (Figure 26) were developed.39, 40 These compounds derived from a 
structural simplification of a class of 1,8-naphthyridine-3-carboxamides previously 
designed in laboratory where I performed my thesis, as a series of selective CB2 
receptor agonists, which exhibited interesting pharmacological properties like anti-
proliferative activity in cancer cells and immuno-modulatory activity in models of 
neuroinflammation.40 
 
 
 
Figure 26. 2-Oxo-1,2-dihydropyridine-3-carboxamide derivatives A. 
 
Compounds A presented all the features required for the preservation of good 
CB1/CB2 selectivity: a central lipophilic core (the 2-oxo-1,2-dihydropyridine 
nucleus) connected with a nonaromatic carboxamide group in position 3, and a 
lipophilic substituent at the 1-position with an H-bond acceptor atom. 
2-Oxo-1,2-dihydropyridine-3-carboxamide derivatives A exhibited high affinity and 
interesting selectivity towards the CB2 receptor. Regarding to the structural 
modifications in the position 1 of the 2-oxo-pyridine nucleus, the p-fluorobenzyl 
A 
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substituent results important in determining the maintenance of the affinity 
towards both receptor subtypes: in fact derivatives with this substituent in N1-
position showed the highest CB2 receptor affinity. 
Replacement of the cycloheptylamide with other cycloamide groups in position 3 
of the 2-oxo-pyridine nucleus of compound A decreased the receptor affinities. 
Moreover, the shift of the substituent in N-1 position to the oxygen in position 2 of 
the heterocyclic nucleus gave derivatives that showed low affinity.40 
The significant affinity towards CB2 receptor displayed by some of derivatives with 
general structure A made this new scaffold useful as initial building block for 
designing CB2 receptor ligands. Furthermore some of these CB2 receptor ligands 
were effective on different tumor cell lines (human breast carcinoma, human 
prostate carcinoma, human gastric adenocarcinoma, glioblastoma). 
Antiproliferative effect of these compounds was mediated by the CB2 receptor, 
indeed they decreased the CB2 receptor expression levels and their effect was 
reverted by the CB2 antagonist. 
 
Subsequently, the introduction of a substituent in position 5 of the heterocyclic 
nucleus (compounds B, Figure 27) showed an interesting effect on the activity on 
the CB2 receptor. Indeed, the nature of this substituent determined the control of 
the switch among the different types of pharmacological modulation: agonism, 
inverse agonism or antagonism on the receptor. In particular, replacing the 
hydrogen atom in position 5 with a phenyl group (B1) or with a 4-methoxyphenyl 
group (B2), the CB2 receptor activity shifted from agonism to inverse agonism and 
antagonism, respectively. Conversely, substituting the hydrogen with a bromine 
atom (B3) the CB2 receptor activity did not vary.  
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Figure 27. The position C-5 of the 2-oxopyridine nucleus permitted the identification of the “key” 
position to be substituted on the 1,2-dihydro-2-oxopyridine scaffold responsible for functionality 
switch within this series of compounds. 
 
 
Subsequently the 5-substituted 2-oxo-1,2-dihydropyridine-3-carboxamide 
derivatives B were modified through the insertion of a methyl group at the 
position C-6 or C-4 to obtain compounds C and D (Figure 28). 
These compounds were tested in order to evaluate the influence of a small 
substituent at the position 4 or 6 of the heterocyclic nucleus on the CB receptors 
affinity.  
    A 
Agonist 
         B1 
Inverse agonist 
 
            B2 
Antagonist 
 
   B3 
Agonist 
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Figure 28. Development of compounds with general structures C and D. 
 
Compounds of both series showed not only the best binding properties at CB2 
receptor (Table 3), but also the same behaviour towards these receptors in term of 
functional activity. 
Furthermore, the 6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives C 
showed also inhibition of AEA and 2-AG uptake with IC50 values in the nM range. 
Finally some of these ligands showed to inhibit the fatty acid amide hydrolase 
(FAAH) (Table 4) and none of the tested compounds induced inhibition of MAGL 
and ABHDs activities.  
    B 
    C 
    D 
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Table 3   Radioligand binding data of 6-substituted-2-oxo-1,2-dihydropyridine derivatives 
 
   
 
 R1 R2 Ki (nM) 
CB1a CB2b SIc 
C1 p-Fluorobenzyl H 14.2 9.4 3.3 
C2 p-Fluorobenzyl Phenyl 176 5.6 31.4 
C3 p-Fluorobenzyl p-Methoxyphenyl 9.8 26.2 0.4 
C4 p-Fluorobenzyl Br 8.9 2.8 3.1 
C5 p-Fluorobenzyl F 5.2 5.4 0.9 
C6 p-Fluorobenzyl Cl 4 0.6 6.8 
C7 p-Fluorobenzyl I 1921 1230 1.6 
D1 p-Fluorobenzyl H 9.2 0.4 23 
D2 p-Fluorobenzyl Br 4.5 1.1 4.1 
D3 p-Fluorobenzyl Phenyl 23.1 3.9 5.8 
D4 p-Fluorobenzyl p-Methoxyphenyl 3.2 7.36 0.4 
 
a Affinity of compounds for CB1 receptor was evaluated using membranes from CHO cells transfected and [3H]CP-55,940. 
b Affinity of compounds for CB2 receptor was evaluated using membranes from CHO cells transfected and [3H]CP-55,940. 
c Selectivity index for CB2 receptor calculated as Ki(CB1R)/Ki(CB2R) ratio. 
 
 
 Table 4   Evaluation of 6-methyl-2-oxo-1,2-dihydropyridine derivatives on FAAH and on putative 
endocannabinoid transporter (EMT) 
 R1 R2 EC50 (µM) EC50 (µM) Selectivity 
over FAAH 
EMT FAAH  
C1 p-Fluorobenzyl H ≥ 10 4.37 - 
C2 p-Fluorobenzyl Phenyl 0.098 0.086 0.9 
C3 p-Fluorobenzyl p-Methoxyphenyl 0.082 0.246 3 
C4 p-Fluorobenzyl Br 1.63 0.855 0.5 
D1 p-Fluorobenzyl Phenyl - 213  
  
    C     D 
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Therefore some of these compounds, which are able to modulate more than one 
target of the ECS, might be exploited to investigate the multi-target approach for 
modulating the ECS and then they could be useful for the treatment of different 
pathological conditions like cancer and neurodegenerative diseases. 
 
In the light of these good results, with the aim to deepen the structure activity 
relationship (SAR) of this series of compounds, during my thesis work, derivatives 
with general structures E and F were designed and synthesized as analogs of 
compounds C and D in which the amide group in position C-3 was substituted by 
the corresponding reverse amide (Figure 29). 
 
 
 
 
 
 
 
 
           R2 = H, Br, Cl, F, phenyl, p-methoxyphenyl. 
 
Figure 29. Development of compounds with general structures E and F.  
    F 
    E     C 
    D 
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Thus, I designed and synthesized compounds E1-E6 and F1-F5 (Table 5). 
 
   Table 5   Compounds designed and synthesized during my thesis work 
      
 
E F 
                   R2                    R2 
E1 Phenyl F1 H 
E2 H F2 Br 
E3 Br F3 p-Methoxyphenyl 
E4 p-Methoxyphenyl F4 Phenyl 
E5 Cl F5 Cl 
E6 F 
 
 
All the substituents of compounds E and F have been chosen considering the 
best results obtained with previous compounds. The novel ligands are 
characterized by a p-fluorobenzyl group in position 1 of the pyridine nucleus 
and a cycloheptanecarboxamide in position 3. Hydrogen, bromine, chloro, 
fluoro, phenyl and p-methoxyphenyl are chosen as substituents  in position 5 
(R2) of the pyridine nucleus.  
    E     F 
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Synthesis 
Synthesis of N-(6-methyl-2-oxo-1,2-dihydropyridin-3-yl)cycloheptanecarboxamide 
derivatives E 
 
The synthesis of N-(6-methyl-2-oxo-1,2-dihydropyridin-3-
yl)cycloheptanecarboxamide derivatives E1-E6 (Figure 30) was initially planned 
following the synthetic pathway showed in Scheme 1. This synthetic route was 
used only to synthesize compound E1, as the yields were very low. 
 
 
E1   R2 = Phenyl; 
E2   R2 = H; 
E3   R2 = Br; 
E4   R2 = p-Methoxyphenyl; 
E5   R2 = Cl; 
E6   R2 = F. 
 
Figure 30. Design of compounds E1-E6.  
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Scheme 1.  Synthetic route for compounds E 
 
 
 
Reagents and conditions:  a) 1) NaH 60%, DMF, 4-fluorobenzyl chloride, 50°C, 24h  2) NaOH 
10% reflux, 4h  3) HCl 10%;  b) 1) NaH 60%, LiBr, 4-fluorobenzyl chloride, DMF, DME, 65°C, 
overnight  2) NaOH 60% reflux, 4h  3) HCl;  c) tert-butyl alcohol, diphenylphosphoryl azide, 
potassium tert-butoxide, reflux, overnight;  d) Br2, CHCl3, rt, overnight;  e) Triphenylphosphine, 
Pd(OAc)2, toluene, K2CO3, phenylboronic acid, 100°C, overnight;  f) HCl 37%, rt, 1h;  g) 1) 
Cycloheptancarboxilic acid, SOCl2, 76°C, 3h  2) Toluene, NEt3, 0-25°C, overnight. 
 
The synthetic route started with a N-alkylation reaction carried out treating a 
solution of commercially available 6-methyl-2-oxo-1,2-dihydropyridine-3-
carboxylic acid in anhydrous DMF with NaH 60%, and, after 2 hours, adding 4-
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fluorobenzyl chloride. The reaction mixture was stirred at 50°C for 24 hours. The 
treatment of the crude residue with NaOH 10% and then with HCl 10% gave the 
desired N-alkylated derivative 1 in very low yields. To increase the yield, the same 
reaction was performed increasing the temperature and/or the percentage of NaH 
60%, but unsuccessfully. 
Furthermore the reaction conditions were changed: LiBr was used in addiction to 
NaH 60%. These conditions favour the synthesis of N-functionalized product.42, 43 In 
these conditions yield of compound 1 increased (Table 6). 
 
Table 6   Attempts, conditions and yields of N-alkylation 
 
 
Attempts Reagents and conditions Yields 
a 
1) DMF, NaH 60% (1.2 eq), rt, 2h 
2) 4-fluorobenzyl chloride, 50°C, 24h 
8.5% 
b 
1) DMF, NaH 60% (1.2 eq), rt, 2h 
2) 4-fluorobenzyl chloride, 70°C, 24h 
17% 
c 
1) DMF, NaH 60% (2 eq), rt, 2h 
2) 4-fluorobenzyl chloride, 70°C, 24h 
5% 
d 
1) DMF, NaH 60% (2.5 eq), rt, 2h 
2) 4-fluorobenzyl chloride, 70°C, 24h 
9 – 17% 
e 
1) DMF/DME in ratio 1:4, NaH 60%, LiBr 
(2 eq), 0°C-rt 
2) 4-fluorobenzyl chloride, 65°C, 
overnight 
30 – 40% 
  
56 
 
Compound 1 was submitted to Curtius reaction (Figure 31), which was performed 
using tert-butyl alcohol, diphenylphosphoryl azide, potassium tert-butoxide and 
refluxing the mixture. The purification of the crude residue by flash 
chromatography provided the derivative 2 in 20% yield. 
 
 
Figure 31. Mechanism of Curtius reaction. 
 
In order to improve yields, Curtius reaction was carried out before N-alkylation 
(Scheme 2) but in this way the yields did not change. Furthermore each steps of 
this procedure required a purification by flash chromatography, while in the first 
case showed in Scheme 1 only a purification by flash chromatography was needed.  
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Scheme 2.  Attempt to improve yields reversing the first two steps of Scheme 1 
 
 
 
Reagents and conditions:  a) 1) DPPA, NEt3, dioxane, 100°C, 2h  2) tert-butyl alcohol, reflux, 
overnight;  b) NaH 60%, DMF, 4-fluorobenzyl chloride, 70°C, overnight. 
 
Compound 2 was treated with a solution of bromine in CHCl3 (Scheme 1) to afford 
the corresponding derivative 3.44 
The 5-bromo derivative 3 was then subjected to a Suzuki-Miyaura cross-coupling 
reaction45 (Figure 32) with the phenylboronic acid in toluene in the presence of 
tetrakis(trisphenylphosphine)palladium(0) as catalyst and anhydrous potassium 
carbonate as base, stirred at 100°C overnight to afford compound 4.46 Palladium(0) 
compound required in this cycle, Pd(PPh3)4, was prepared in situ using 
triphenylphosphine (PPh3) and palladium acetate (Pd(OAc)2). Compound 4 was 
purified by flash chromatography (Scheme 1). 
 
 
Figure 32. Suzuki-Miyaura cross-coupling reaction mechanism.45 
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As described in Scheme 1, compound E1 was obtained via a two-step procedure 
starting from compound 4. First of all, a deprotection of the amine group through 
a hydrolysis with HCl 37% occurred and compound 5 was obtained. The second 
step involved the formation of the amide moiety in position 3 through the reaction 
between compound 5 and the suitable acyl chloride in toluene and triethylamine 
at 0°C. The acyl chloride was obtained by the reaction between 
cycloheptanecarboxylic acid and SOCl2 at 76°C for 3 hours. 
The mixture was purified by flash chromatography to afford compound E1 
(Scheme 1). 
 
As reported in Scheme 3, compound 3 was converted in compound 6 by a 
hydrolysis carried out with HCl 37%. 
Unfortunately the subsequent reaction of amide formation through the acyl 
chloride to obtain compound E3, failed. 
 
Scheme 3.  Attempt for preparation of compound E3 
 
 
 
Reagents and conditions:  a) HCl 37%, rt, 1h;  b) 1) Cycloheptancarboxilic acid, SOCl2, 76°C, 3h  
2) Toluene, NEt3, 0-25°C, overnight. 
 
 
Alternatively, a new synthetic pathway was developed to afford all the other 
desired compounds E (Scheme 4).  
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Scheme 4.  Synthetic route for compounds E2-E7 
 
 
 
Reagents and conditions:  a) H2, Pd/(C), MeOH, rt, overnight;  b) Cycloheptancarboxilic acid, 
TBTU, NEt3, DMF, 0°C-rt, overnight;  c) NaH 60%, LiBr, 4-fluorobenzyl chloride, DMF, DME, 
65°C, overnight;  d) Br2, CHCl3, rt, overnight;  e) Triphenylphosphine, Pd(OAc)2, toluene, 
K2CO3, p-methoxyphenylboronic acid, 110°C, overnight;  f) N-chlorosuccinimide, ACN, reflux, 
overnight;  g)  Selectfluor™, ACN, reflux, overnight;  h) N-iodosuccinimide, ACN, reflux, 
overnight. 
 
The key intermediate of this synthetic route is N-(6-methyl-2-oxo-1,2-
dihydripyridin-3-yl)cycloheptanecarboxamide 8, useful for the synthesis of all the 
other desired compounds E2-E7. 
This derivative was obtained via a two-step procedure. Firstly, the commercially 
available 2-hydroxy-6-methyl-3-nitropyridine was undergone to catalitic 
hydrogenation, using Pd/C as a catalyst, to afford compound 7. 
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After, cycloheptanecarboxylic acid was treated with the coupling agent 2-[(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate] (TBTU) at 0 °C, 
in presence of triethylamine to afford the corresponding activated benzotriazolyl-
ester (Figure 33), and then 2-hydroxy-6-methyl-3-aminopyridine (7) was added to 
give the desired carboxamide derivative 8, which was purified by flash 
chromatography. 
 
 
Figure 33. Proposed mechanism for the amide bond formation through TBTU. 
 
Compound 8 was easily converted in compound E2 through N-alkylation in 
presence of NaH 60%, LiBr and 4-fluorobenzyl chloride, heating at 65°C overnight. 
The derivative E2 was purified by flash chromatography. 
 
As reported in Scheme 4, compound 8 was treated with a solution of bromine in 
CHCl3 to afford compound 9, which was submitted to a N-alkylation reaction, in 
the same conditions previously described, to afford desired compound E3, which 
was purified by flash chromatography. This compound was subjected to a Suzuki 
cross-coupling reaction with the p-methoxyphenylboronic acid in toluene in the 
presence of tetrakis(trisphenylphosphine)palladium(0) as catalyst and anhydrous 
potassium carbonate as base, stirred at 110°C overnight to afford compound E4. 
Palladium(0) compound required in this cycle, Pd(PPh3)4, was prepared in situ 
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using triphenylphosphine (PPh3) and palladium acetate (Pd(OAc)2). Compound E4 
was purified by flash chromatography. 
 
In order to obtain the 5-chlorinated-3-carboxamide derivative 10 (Scheme 4), 
compound 8 was treated with N-chlorosuccinimide using acetonitrile as solvent 
and refluxing overnight. Compound 10 was purified by flash chromatography. 
From this reaction, compound 11 was obtained in very low yields. The structure of 
compound 11 was verified by 1H-NMR analysis since the protons of the 
chloromethyl group in 6-position are deshielded, therefore they display a 
resonance signal (singulet), that integrate for 2H, at low field. 
Derivative 10 was alkylated with the same procedure previously reported, to 
afford desired compound E5, which was purified by flash chromatography. 
Compound 11 was then alkylated with NaH 60%, LiBr and 4-fluorobenzyl chloride, 
heating at 65°C. Unfortunately, this reaction gave a mixture difficult to purify and 
the compound was not isolated (Scheme 4). 
 
As reported in Scheme 4, the carboxamide 8 was treated with the fluorinating 
agent Selectfluor™ (1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane 
bis(tetrafluoroborate)47, 48, 49, 50, 51 in refluxing acetonitrile for 12 hours, to afford 
the corresponding 5-fluorinated derivative 12, which was purified by flash 
chromatography.52 
Derivative 12 was alkylated with the same procedure previously used, to yield 
desired compound E6. In this case, the O-alkylated derivative E7 was also isolated. 
The structures of compounds E6-E7 were verified by 1H-NMR analysis. The two 
isomers were distinguished since the methylene protons connected to the oxygen 
atom are more deshielded, therefore they display a resonance signal (singulet) at 
lower field than the two methylene protons bonded to the nitrogen atom. 
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Following the approach previously described for compound 10, the 5-iodinated-3-
carboxamide derivative was tried to be synthesized (Scheme 4). 
Compound 8 was treated with N-iodosuccinimide, using acetonitrile as solvent, 
and refluxing overnight. Unfortunately, this reaction gave a mixture difficult to 
purify and the compound was not isolated.  
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Synthesis of N-(4-methyl-2-oxo-1,2-dihydropyridin-3-yl)cycloheptanecarboxamide 
derivatives F 
 
The synthesis of N-(4-methyl-2-oxo-1,2-dihydropyridin-3-
yl)cycloheptanecarboxamide derivatives F1-F5 (Figure 34) was planned following 
Scheme 5. 
 
 
F1   R2 = H; 
F2   R2 = Br; 
F3   R2 = p-Methoxyphenyl; 
F4   R2 = Phenyl; 
F5   R2 = Cl. 
 
Figure 34. Design of compounds F1-F5.  
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Scheme 5.  Synthetic route for compounds F1-F5 
 
 
 
Reagents and conditions:  a) H2, Pd/(C), MeOH, rt, overnight;  b) 1) Cycloheptancarboxilic acid, 
SOCl2, 76°C, 3h  2) Toluene, DMF, NEt3, 0-32°C, 48h;  c) 1) DMF, CsF, rt, 1h  2) 4-fluorobenzyl 
chloride, 50°C, overnight;  d) Br2, CHCl3, 30°C, overnight;  e) Triphenylphosphine, Pd(OAc)2, 
toluene, K2CO3, un/substituted-phenylboronic acid, 110°C, overnight;  f) N-chlorosuccinimide, 
ACN, reflux, overnight;  g) Selectfluor™, ACN, reflux, overnight. 
 
Commercially available 2-hydroxy-4-methyl-3-nitropyridine was undergone to 
catalitic hydrogenation, to afford derivative 13, which was treated with the 
coupling reagent TBTU at 0°C, in presence of cycloheptanecarboxilic acid and 
triethylamine. This last reaction failed, so the conditions were changed: the same 
reaction was performed increasing the temperature, but unsuccessfully. 
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The reason of this resistence is probably correlated to the steric hindrance of 
derivative 13, due to the presence of the methyl group in position 4. For this 
reason, the amino group in position 3 of the pyridine ring was not probably able to 
attack the carbonyl moiety of benzotriazolyl-ester (Figure 35). 
 
 
Figure 35. Probable reason of the failure of carboxamide derivative synthesis via TBTU. 
 
Then the attention was focused on the pathway to synthesize the carboxamide 
derivative 14 through the involvement of acyl chloride, more reactive than 
benzotriazolyl-ester. 
 
The reaction between the amine derivative 13 with the cycloheptanecarbonyl 
chloride in toluene, DMF and triethylamine at 0°C, and then at 32°C for 48 hours 
afforded compound 14. The acyl chloride was obtained by the reaction between 
cycloheptanecarboxylic acid and SOCl2 at 76°C for 3 hours. Derivative 14 was 
purified by flash chromatography. 
Compound 14 was then N-alkylated for reaction with 4-fluorobenzyl chloride in 
presence of NaH 60%, LiBr and heating at 65°C overnight. Because the yield of this 
step was less than 10%, the reaction conditions were changed. Then, compound 14 
was dissolved in DMF and treated with CsF for 1 hour before adding 4-fluorobenzyl 
chloride.53 The reaction mixture was stirred at 50°C overnight, to afford desired 
compound F1, in 40% yield. Derivative F1 was purified by flash chromatography. 
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Compound 14 was treated with a solution of bromine in CHCl3, heating at 30°C to 
afford compound 15, which was N-alkylated using CsF and 4-fluorobenzyl chloride, 
to obtain desired compound F2, which was purified by flash chromatography. 
In order to obtain compounds F3 and F4, derivative F2 was submitted to a Suzuki 
cross-coupling reaction. Thus, toluene, triphenylphosphine and palladium acetate 
were mixed together to afford the catalyst 
tetrakis(trisphenylphosphine)palladium(0). After, potassium carbonate, compound 
F2 and the suitable boronic acid (p-methoxyphenylboronic acid or phenylboronic 
acid) were added and heated at 110°C overnight to afford the desired compounds 
F3 and F4, which were purified by flash chromatography. 
 
In order to obtain the 5-chlorinated derivative 16 (Scheme 5), compound 14 was 
treated with N-chlorosuccinimide using acetonitrile as solvent, and refluxed 
overnight. Derivative 16 was then alkylated, following the same procedure used to 
obtain compounds F1-F4. Desired compound F5 was purified by flash 
chromatography. 
 
As reported in Scheme 5, the carboxamide 14 was treated with the fluorinating 
agent Selectfluor™ in refluxing acetonitrile for 12 hours, to afford the 
corresponding 5-fluorinated derivative 17. Compound 17 was purified by flash 
chromatography. Derivative 17 was alkylated with the same procedure previously 
used. Unfortunately, the amount of the obtained product was not enough to be 
purified by flash chromatography.  
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Results and Discussion 
 
Compounds E1-E7 and F1-F5 are being tested for their activity and binding affinity 
(Ki values) towards both subtypes of CB receptors at the Institute of Biochemistry 
and Molecular Medicine of the University of Bern.  
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CB1 and CB2 receptor affinity 
Until now, the preliminary screening of N-(6-methyl-2-oxo-1,2-dihydropyridin-3-
yl)cycloheptanecarboxamide derivatives E2, E3 and E5 is available. The binding 
affinities of these compounds (Ki values) are evaluated in competitive radioligand 
displacement assays against [3H]CP-55,940 using membrane preparations obtained 
in-house from stable transfected CHO-hCB1 and CHO-hCB2 cells. The results are 
summarized in Table 7, where are also indicated Ki values of 6-methyl-2-oxo-1,2-
dihydropyridine-3-carboxamide derivative C1, C4 and C6, previously synthesized in 
laboratory where I performed my thesis. 
 
Table 7   Radioligand binding data of N-(6-methyl-2-oxo-1,2-dihydropyridin-3-yl)cycloheptane 
carboxamide derivatives E2, E3 and E5, and 6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 
derivatives C1, C4 and C6 
 
    
 
 R2 Ki (nM) 
CB1a CB2b SIc 
C1 H 14.2 9.4 3.3 
C4 Br 8.9 2.8 3.1 
C6 Cl 4 0.6 6.8 
E2 H  118.34  
E3 Br  129.86  
E5 Cl  62.58  
 
a Affinity of compounds for CB1R was evaluated using membranes from CHO cells transfected and [3H]CP-55,940. 
b Affinity of compounds for CB2R was evaluated using membranes from CHO cells transfected and [3H]CP-55,940. 
c Selectivity index for CB2R calculated as Ki(CB1R)/Ki(CB2R) ratio.  
    E     C 
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The preliminary screening on cannabinoid receptors of compounds E shows that 
these compounds possess interesting affinity for CB2 receptor, but they are less 
active than the corresponding derivatives C. Subsequently there is an increase in 
the Ki values for compounds E. These results indicate that the reverse amide group 
does not interact with the binding site of CB2 receptor in the same way of the 
amide. However the new compounds E and F need further investigations in order 
to check their activity on other targets of the ECS.  
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Experimental part 
 
Commercially available reagents were purchased from Sigma Aldrich or Alpha 
Aesar and used without purification. 
The structure of all compounds was verified by means of spectrometry 1H-NMR 
and 13C-NMR. The spectra of proton nuclear magnetic resonance were performed 
with a Bruker AVANCE III™ 400 spectrometer operating at 400 MHz and referred to 
the residual solvent. Chemical shift (δ) are reported in parts per million, while 
coupling constants (J) are expressed in Hertz (Hz). 
Evaporation was performed under vacuum using a rotary evaporator. 
The system for isocratic flash chromatography includes glass chromatography 
columns and silica gel 60 Å (0.040-0.063 mm; MERK). 
Reactions were monitored by TLC. The analytical TLC plates were performed using 
silica gel 60 F254 (MERCK) containing a fluorescent indicator; the various spots were 
highlighted by means of a UV lamp (254 nm). 
Melting points were determined on a Kofler® hot stage apparatus and are 
uncorrected. 
Catalitic hydrogenation was performed with CLAIND H2 generator, type HG2200 
(flow meter: 200 ml/min; outlet pressure: 1-6 bar; operating temperature: 5-40°C).  
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1-(4’-fluorobenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-
carboxylic acid (1) 
 
 
 
To a solution of commercially available 6-methyl-2-oxo-1,2-dihydropyridine-3-
carboxylic acid (0.200 g, 1.30 mmol) in DME (2.60 ml) and anhydrous DMF (0.650 
ml), NaH 60% (0.0536 g, 1.34 mmol) was added portionwise under nitrogen at 0°C. 
LiBr (0.226 g, 2.60 mmol) was added 10 minutes later. The reaction contents were 
stirred 15 minutes at room temperature, 4-fluorobenzyl chloride (0.300 ml, 2.50 
mmol) was added dropwise and the reaction was stirred at 65°C overnight. 
The solvents were removed under reduced pressure. 
The reaction mixture was dissolved in ethyl acetate and washed six times with 
brine. Then the organic phase was dried over anhydrous Na2SO4, filtered and 
evaporated under reduced pressure. 
NaOH 60% (4.00 ml) was added to the crude residue obtained and the reaction 
contents were refluxed at 130°C for 4 hours. 
The reaction mixture was extracted with CHCl3 and concentrated HCl was added to 
the aqueous phase until pH=2. The aqueous phase was extracted with CHCl3. Then 
the organic phase was dried over anhydrous Na2SO4, filtered and evaporated 
under reduced pressure to afford compound 1 (0.139 g, 0.528 mmol) as a yellow 
solid. 
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Yield: 41% 
1H-NMR: (DMSO) δ (ppm) 8.38 (d, J=7.6 Hz, 1H, H4 Py), 7.31-7.20 (m, 4H, Ar), 6.75 
(d, J=7.6 Hz, 1H, H5 Py), 5.48 (s, 2H, benzylic CH2), 2.53 (s, 3H, CH3).  
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Tert-butyl [1-(4’-fluorobenzyl)-6-methyl-2-oxo-1,2-
dihydropyridin-3-yl]-carbamate (2) 
 
 
 
1-(4’-fluorobenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid 1 (0.215 
g, 0.820 mmol) was dissolved in tert-butyl alcohol (14.4 ml) under heating and 
then diphenylphosphoryl azide (0.150 ml, 0.680 mmol) and potassium tert-
butoxide (0.0766 g, 0.680 mmol) were added. 
The reaction contents were refluxed at 100°C overnight. 
The reaction mixture was extracted with CHCl3/water and then the organic phase 
was dried over anhydrous Na2SO4, filtered and evaporated under reduced 
pressure. 
The brown oil obtained was purified by flash chromatography on silica gel using, as 
eluent, petroleum ether/ethyl acetate 8:2, to obtain compound 2 (0.235 g, 0.709 
mmol) as a light brown oil. 
 
Yield: 35% 
1H-NMR: (CDCl3) δ (ppm) 7.91 (d, J=7.2 Hz, 1H, H4 Py), 7.61 (bs, 1H, NH amide), 
7.12-7.09 (m, 2H, Ar), 7.01-7.97 (m, 2H, Ar), 6.08 (d, J=7.6 Hz, 1H, H5 Py), 5.32 (s, 
2H, benzylic CH2), 2.26 (s, 3H, CH3), 1.50 (s, 9H, tert-butyl).   
74 
 
Tert-butyl [5-bromo-1-(4’-fluorobenzyl)-6-methyl-2-oxo-1,2-
dihydropyridin-3-yl]-carbamate (3) 
 
 
 
Tert-butyl [1-(4’-fluorobenzyl)-6-methyl-2-oxo-1,2-dihydropyridin-3-yl]-carbamate 
2 (0.235 g, 0.708 mmol) was dissolved in CHCl3 (1.18 ml) at room temperature. 
A solution of Br2 (0.0400 ml, 0.708 mmol) in CHCl3 (0.708 ml), previously prepared, 
was added dropwise to the first solution. The reaction contents were allowed to 
stir at room temperature overnight. 
The reaction mixture was washed two times with a satured solution of Na2S2O3. 
Then the organic phase was dried over anhydrous Na2SO4, filtered and 
concentrated in vacuum to afford compound 3 (0.206 g, 0.502 mmol) as a light 
brown oil. 
 
Yield: 71% 
1H-NMR: (CDCl3) δ (ppm) 8.20 (bs, 1H, NH amide), 7.63 (s, 1H, H4 Py), 7.26-6.99 
(m, 4H, Ar), 5.37 (s, 2H, benzylic CH2), 2.41 (s, 3H, CH3), 1.51 (s, 9H, tert-butyl).  
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Tert-butyl [1-(4’-fluorobenzyl)-6-methyl-2-oxo-5-phenyl-1,2-
dihydropyridin-3-yl]-carbamate (4) 
 
 
 
0.00368 g (0.0150 mmol, 0.0300 equivalents) of Pd(OAc)2 were placed in a solution 
of 0.0197 g (0.0750 mmol) of PPh3 in toluene in a vial under nitrogen. 
After 10-15 minutes, phenylboronic acid (0.125 g, 1.00 mmol), K2CO3 (0.104 g, 
0.753 mmol) and tert-butyl [5-bromo-1-(4’-fluorobenzyl)-6-methyl-2-oxo-1,2-
dihydropyridin-3-yl]-carbamate 3 (0.206 g, 0.502 mmol) were added to reaction. 
Reaction contents were allowed to stir at 100°C overnight. 
After the completion of the reaction, toluene was removed; reaction mixture was 
extracted with CHCl3/water. Combined organic phase was dried over Na2SO4 and 
evaporated to obtain a brown oil. 
The crude residue obtained was purified by flash chromatography on silica gel 
using, as eluent, petroleum ether/ethyl acetate 9:1 to give compound 4 (0.0835 g, 
0.204 mmol) as a yellow oil. 
 
Yield: 41% 
1H-NMR: (CDCl3) δ (ppm) 8.03 (bs, 1H, NH amide), 7.68 (s, 1H, H4 Py), 7.38-7.31 
(m, 2H, Ar), 7.31-7.28 (m, 1H, Ar), 7.24-7.15 (m, 2H, Ar), 7.14-7.13 (m, 2H, Ar), 
7.03-6.99 (m, 2H, Ar), 5.43 (s, 2H, benzylic CH2), 2.20 (s, 3H, CH3), 1.49 (s, 9H, tert-
butyl).  
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3-amino-1-(4’-fluorobenzyl)-6-methyl-5-phenylpyridin-2(1H)-
one (5) 
 
 
 
To a solution of tert-butyl [1-(4’-fluorobenzyl)-6-methyl-2-oxo-5-phenyl-1,2-
dihydropyridin-3-yl]-carbamate 4 (0.0339 g, 0.0829 mmol) in ethyl acetate (1.39 
ml), HCl 37% (0.270 ml, 3.32 mmol) was added. 
Reaction contents were allowed to stir at room temperature for 1 hour. 
The reaction mixture was extracted with CHCl3/water. Combined organic phase 
was dried over Na2SO4 and evaporated to afford compound 5 (0.0305 g, 0.0989 
mmol) as a brown oil. 
 
Yield: over 99% 
1H-NMR: (CDCl3) δ (ppm) 7.39-6.98 (m, 9H, Ar), 6.61 (s, 1H, H4 Py), 5.42 (s, 2H, 
benzylic CH2), 2.17 (s, 3H, CH3).  
77 
 
N-[1-(4’-fluorobenzyl)-6-methyl-2-oxo-5-phenyl-1,2-
dihydripyridin-3-yl]cycloheptanecarboxamide (E1) 
 
 
 
Cycloheptanecarboxylic acid (0.0140 ml , 0.0989 mmol) was dissolved in SOCl2 
(0.105 ml, 1.44 mmol) in a vial under nitrogen. The solution was stirred at 76°C for 
3 hours to allow the acyl chloride to generate. 
In the meantime, 3-amino-1-(4’-fluorobenzyl)-6-methyl-5-phenylpyridin-2(1H)-one 
5 (0.0305 g, 0.0989 mmol) was dissolved in toluene (4.58 ml) in a round bottom 
flask. After the dissolution, triethylamine (0.0300 ml, 0.198 mmol) was added and 
the temperature was lowered to 0°C. 
After 3 hours, the solution in the vial was cooled to room temperature and then 
SOCl2 was removed under nitrogen. 
The acyl chloride formed was added dropwise, under nitrogen, to the solution in 
the the round bottom flask previously prepared and the reaction contents were 
allowed to stir at 25°C overnight. 
After the completion of the reaction, toluene was removed; reaction mixture was 
extracted with ethyl acetate/water and washed with a satured solution of 
NaHCO3. Combined organic phase was dried over Na2SO4 and evaporated to 
obtain a yellow oil. 
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The yellow oil obtained was purified by flash chromatography on silica gel using, as 
eluent, petroleum ether/ethyl acetate 8:2 to give compound E1 (0.00570 g, 0.0132 
mmol) as a yellow oil. 
 
Yield: 13% 
1H-NMR: (CDCl3) δ (ppm) 8.44 (s, 1H, H4 Py), 8.37 (bs, 1H, NH amide), 7.37-7.00 
(m, 9H, Ar), 5.43 (s, 2H, benzylic CH2), 2.47-2.42 (m, 1H, CH cycloheptyl), 2.23 (s, 
3H, CH3), 1.98-1.1.94 (m, 2H, cycloheptyl), 1.80-1.70 (m, 4H, cycloheptyl), 1.58-
1.46 (m, 6H, cycloheptyl). 
13C-NMR: (CDCl3) δ (ppm) 176.33, 160.93, 158.08, 139.13, 131.86, 129.70, 128.39, 
128.15, 128.07, 126.61, 125.09, 121.21, 115.96, 115.74, 48.32, 48.02, 31.54, 28.28, 
26.46, 17.42.  
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3-Amino-5-bromo-1-(4’-fluorobenzyl)-6-methyl-2(1H)-one (6) 
 
 
 
To a solution of tert-butyl [5-bromo-1-(4’-fluorobenzyl)-6-methyl-2-oxo-1,2-
dihydropyridin-3-yl]-carbamate 3 (0.138 g, 0.336 mmol) in ethyl acetate (5.62 ml), 
HCl 37% (1.10 ml, 13.43 mmol) was added. 
Reaction contents were allowed to stir at room temperature for 1 hour. 
The reaction mixture was extracted with CHCl3/water. Combined organic phase 
was dried over Na2SO4 and evaporated to give compound 6 (0.116 g, 0.373 mmol) 
as a brown oil. 
 
Yield: over 99% 
1H-NMR: (CDCl3) δ (ppm) 8.02 (s, 2H, NH2), 7.13-7.09 (m, 2H, Ar), 7.02-6.97 (m, 2H, 
Ar), 6.83 (s, 1H, H4 Py), 5.37 (s, 2H, benzylic CH2), 2.36 (s, 3H, CH3).  
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2-Hydroxy-6-methyl-3-aminopyridine (7) 
 
 
 
In a solution of commercial available 2-hydroxy-6-methyl-3-nitropyridine (1.00 g, 
6.49 mmol) in methanol, Pd/C (0.100 g) was added. 
The reaction contents underwent catalitic hydrogenation (three alternated cycles 
of vacuum and hydrogen); after that, the reaction contents were allowed to stir 
under hydrogen at room temperature overnight. 
The reaction mixture was filtered under vacuum using celite. The filtrate was 
evaporated under reduced pressure to afford compound 7 (0.823 g, 6.63 mmol) as 
an ocher solid. 
 
Yield: over 99% 
1H-NMR: (CDCl3) δ (ppm) 12.36 (bs, 1H, NH Py), 6.57 (d, J=7.2 Hz, 1H, H4 Py), 5.88 
(d, J=7.2 Hz, 1H, H5 Py), 3.97 (bs, 2H, NH2), 2.25 (s, 3H, CH3).  
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N-(6-methyl-2-oxo-1,2-dihydripyridin-3-
yl)cycloheptanecarboxamide (8) 
 
 
 
A solution of cycloheptanecarboxylic acid (0.870 ml, 6.32 mmol) in anhydrous DMF 
(15.7 ml) was stirred in an ice-bath. TBTU (2.44 g, 7.59mmol) and triethylamine 
(2.40 ml, 17.7mmol) were added at 0°C. After 30 minutes, 2-hydroxy-3-amino-6-
methylpyridine 7 (0.785 g, 6.32 mmol) was added and the reaction contents were 
stirred at 0°C for 30 minutes and then at room temperature overnight. 
The solvent was removed under reduced pressure. 
The reaction mixture was dissolved in CHCl3 and washed ten times with water. The 
organic phase was dried over anhydrous Na2SO4, filtered and evaporated under 
reduced pressure. The brown solid obtained was purified by flash chromatography 
on silica gel using, as eluent, ethyl acetate/petroleum ether 8:2, to obtain a light 
yellow solid. The solid was crystallized in hexane to afford compound 8 as a white 
crystal solid (1.29 g, 5.18 mmol). 
 
Yield: 82% 
1H-NMR: (CDCl3) δ (ppm) 11.77 (bs, 1H, NH Py), 8.39 (d, 1H, J=7.6 Hz, H4 Py), 8.16 
(bs, 1H, NH amide), 6.09 (d, 1H, J=7.6 Hz, H5 Py), 2.47-2.44 (m, 1H, CH cycloheptyl), 
2.32 (s, 3H, CH3), 2.01-1.95 (m, 2H, cycloheptyl), 1.83-1.71 (m, 4H, cycloheptyl), 
1.62-1.49 (m, 6H, cycloheptyl). 
 
Melting point: 182-185°C 
Crystallization solvent: hexane  
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N-[1-(4’-fluorobenzyl)-6-methyl-2-oxo-1,2-dihydripyridin-3-
yl]cycloheptanecarboxamide (E2) 
 
 
 
To a solution of N-(6-methyl-2-oxo-1,2-dihydripyridin-3-yl)-
cycloheptanecarboxamide 8 (0.100 g, 0.403 mmol) in DME (0.810 ml) and 
anhydrous DMF (0.200 ml) NaH 60% (0.0166 g, 0.415 mmol) was added 
portionwise at 0°C.  
LiBr (0.0700 g, 0.806 mmol) was added 10 minutes later. The reaction contents 
were stirred 15 minutes at room temperature, 4-fluorobenzyl chloride (0.0930 ml, 
0.778 mmol) was added dropwise and the reaction was stirred at 65°C overnight. 
The solvents were removed under reduced pressure. 
The reaction mixture was dissolved in CHCl3 and washed three times with brine. 
Then the organic phase was dried over anhydrous Na2SO4, filtered and evaporated 
under reduced pressure. 
The crude residue obtained was purified by flash chromatography on silica gel 
using, as eluent, petroleum ether/ethyl acetate (firstly 9:1 and then 8:2), to give 
compound E2 (0.0377 g, 0.106 mmol) as a yellow oil. 
 
Yield: 26% 
1H-NMR: (CDCl3) δ (ppm) 8.31 (bs, 1H, NH amide), 8.30 (d, 1H, J=7.6 Hz, H4 Py), 
7.01-6.96 (m, 2H, Ar), 7.12-7.08 (m, 2H, Ar), 6.09 (d, 1H, J=7.6 Hz, H5 Py), 5.31 (s, 
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2H, benzylic CH2), 2.45-2.40 (m, 1H, CH cycloheptyl), 2.26 (s, 3H, CH3), 2.02-1.94 
(m, 2H, cycloheptyl), 1.80-1.70 (m, 4H, cycloheptyl), 1.60-1.44 (m, 6H, cycloheptyl). 
13C-NMR: (CDCl3) δ (ppm) 176.99, 161.60, 159.30, 138.52, 132.44, 132.41, 128.85, 
128.77, 122.90, 116.59, 116.38, 107.88, 49.14, 48.18, 32.24, 28.87, 27.20, 20.70. 
 
Crystallization solvent: hexane  
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N-(5-bromo-6-methyl-2-oxo-1,2-dihydripyridin-3-
yl)cycloheptanecarboxamide (9) 
 
 
 
N-(6-methyl-2-oxo-1,2-dihydripyridin-3-yl)-cycloheptanecarboxamide 8 (0.258 g, 
1.04 mmol) was dissolved in CHCl3 (1.73 ml) at room temperature. 
A solution of Br2 (0.0530 ml, 1.04 mmol) in CHCl3 (1.04 ml), previously prepared, 
was added dropwise to the first solution. The reaction contents were allowed to 
stir at room temperature overnight. 
The reaction mixture was washed four times with a satured solution of Na2S2O3. 
Then the organic phase was dried over anhydrous Na2SO4, filtered and 
concentrated in vacuum to give compound 9 (0.304 g, 0.928 mmol) as a light 
yellow solid. 
 
Yield: 89% 
1H-NMR: (CDCl3) δ (ppm) 12.25 (bs, 1H, NH Py), 8.64 (s, 1H, H4 Py), 8.10 (s, 1H, NH 
amide), 2.50-2.41 (m, 1H, CH cycloheptyl), 2.01 (s, 3H, CH3), 1.75-1.61 (m, 6H, 
cycloheptyl), 1.84-1.76 (m, 4H, cycloheptyl), 1.99-1.94 (m, 2H, cycloheptyl).  
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N-[5-bromo-1-(4’-fluorobenzyl)-6-methyl-2-oxo-1,2-
dihydripyridin-3-yl]cycloheptanecarboxamide (E3) 
 
 
 
To a solution of N-(5-bromo-6-methyl-2-oxo-1,2-dihydripyridin-3-yl)-
cycloheptanecarboxamide 9 (0.279 g, 0.854 mmol) in DME (1.70 ml) and 
anhydrous DMF (0.400 ml) NaH 60% (0.0352 g, 0.879 mmol) was added 
portionwise at 0°C.  
LiBr (0.148 g, 1.70 mmol) was added 10 minutes later. The reaction contents were 
stirred 15 minutes at room temperature, 4-fluorobenzyl chloride (0.200 ml, 1.65 
mmol) was added dropwise and the reaction was stirred at 65°C overnight. 
The solvents were removed under reduced pressure. 
The reaction mixture was dissolved in CHCl3 and washed three times with brine. 
Then the organic phase was dried over anhydrous Na2SO4, filtered and evaporated 
under reduced pressure.  
The residue obtained was purified by flash chromatography on silica gel using, as 
eluent, petroleum ether/ethyl acetate (firstly 9:1 and then 8:2), to obtain a light 
yellow solid. 
The solid was crystallized in hexane to afford compound E3 as a white solid (0.150 
g, 0.346 mmol). 
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Yield: 40% 
1H-NMR: (CDCl3) δ (ppm) 8.61 (s, 1H, H4 Py), 8.31 (bs, 1H, NH amide), 7.04-7.00 
(m, 2H, Ar), 7.12-7.09 (m, 2H, Ar), 5.39 (s, 2H, benzylic CH2), 2.46-2.40 (m, 1H, CH 
cycloheptyl), 2.42 (s, 3H, CH3), 1.99-1.94 (m, 2H, cycloheptyl), 1.82-1.71 (m, 4H, 
cycloheptyl), 1.60-1.48 (m, 6H, cycloheptyl). 
13C-NMR: (CDCl3) δ (ppm) 176.38, 161.01, 157.81, 135.69, 131.26, 131.23, 128.14, 
128.06, 125.83, 116.06, 115.85, 101.58, 48.82, 48.28, 31.47, 28.23, 26.44, 19.54. 
 
Melting point: 124-127°C 
Crystallization solvent: hexane  
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N-[1-(4’-fluorobenzyl)-5-(4’-methoxyphenyl)-6-methyl-2-oxo-
1,2-dihydripyridin-3-yl]cycloheptanecarboxamide (E4) 
 
 
 
0.00254 g (0.0104 mmol) of Pd(OAc)2 were placed in a solution of 0.0136 g (0.0519 
mmol) of PPh3 in toluene in a vial under nitrogen. 
After 10-15 minutes, p-methoxyphenylboronic acid (0.107 g, 0.692 mmol), K2CO3 
(0.0717 g, 0.519 mmol) and N-[5-bromo-1-(4’-fluorobenzyl)-6-methyl-2-oxo-1,2-
dihydripyridin-3-yl]-cycloheptanecarboxamide E3 (0.150 g, 0.346 mmol) were 
added to reaction. Reaction contents were allowed to stir at 110°C overnight. 
After the completion of the reaction, toluene was removed; reaction mixture was 
extracted with CHCl3/water. Combined organic phase was dried over Na2SO4 and 
evaporated to afford a brown oil. 
The crude residue obtained was purified by flash chromatography on silica gel 
using, as eluent, petroleum ether/ethyl acetate 8:2 to give compound E4 as a 
yellow oil. 
Compound E4 was crystallized in hexane to afford a yellow oil (0.0306 g, 0.0661 
mmol). 
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Yield: 19% 
1H-NMR: (CDCl3) δ (ppm) 8.43 (s, 1H, H4 Py), 8.38 (bs, 1H, NH amide), 7.16-7.13 
(m, 4H, Ar), 7.05-7.00 (m, 2H, Ar), 6.90-6.88 (m, 2H, Ar), 5.43 (s, 2H, benzylic CH2), 
3.83 (s, 3H, OCH3), 2.48-2.43 (m, 1H, CH cycloheptyl), 2.23 (s, 3H, CH3), 2.00-1.96 
(m, 2H, cycloheptyl), 1.80-1.74 (m, 4H, cycloheptyl), 1.58-1.50 (m, 6H, cycloheptyl). 
13C-NMR: (CDCl3) δ (ppm) 176.58, 161.16, 159.07, 158.28, 135.17, 132.15, 132.12, 
131.03, 128.40, 128.32, 126.75, 125.62, 121.09, 116.19, 115.98, 114.05, 55.57, 
48.58, 48.30, 31.80, 28.52, 26.72, 17.67. 
 
Crystallization solvent: hexane  
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N-(5-chloro-6-methyl-2-oxo-1,2-dihydripyridin-3-
yl)cycloheptanecarboxamide (10) and N-[5-chloro-6-
(chloromethyl)-2-oxo-1,2-dihydropyridin-3-
yl]cycloheptanecarboxamide (11) 
 
    
 
In a suspension of N-(6-methyl-2-oxo-1,2-dihydripyridin-3-yl)-
cycloheptanecarboxamide 8 (0.502 g, 2.02 mmol) and acetonitrile, a solution of N-
chlorosuccinimide (0,270 g, 2.02 mmol) in acetonitrile was added.  
Reaction contents were refluxed at 82°C overnight. 
After the completion of the reaction, the solvent was removed under reduced 
pressure. 
The mixture was quenched with water and extracted with ethyl acetate. 
The organic phase was dried over anhydrous Na2SO4, filtered and concentrated 
under reduced pressure.  
The yellow solid obtained was purified by flash chromatography on silica gel using, 
as eluent, ethyl acetate/petroleum ether (firstly 5:5 and then 6:4), to give 
compound 10 as a white solid and compound 11 as a yellow solid. 
Compound 10 was crystallized in hexane to afford a white solid (0.109 g, 0.385 
mmol). 
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Yield (10): 19% 
1H-NMR (10): (CDCl3) δ (ppm) 11.99 (bs, 1H, NH Py), 8.55 (s, 1H, H4 Py), 8.11 (bs, 
1H, NH amide), 2.50-2.48 (m, 1H, CH cycloheptyl), 2.39 (s, 3H, CH3), 2.01-1.96 (m, 
2H, cycloheptyl), 1.85-1.81 (m, 4H, cycloheptyl), 1.79-1.54 (m, 6H, cycloheptyl). 
 
Melting point (10): 240-246°C 
Crystallization solvent (10): hexane 
 
 
Yield (11): 10% 
1H-NMR (11): (CDCl3) δ (ppm) 8.53 (s, 1H, H4 Py), 8.26 (bs, 1H, NH amide), 4.63 (s, 
2H, CH2Cl), 2.54-2.49 (m, 1H, CH cycloheptyl), 2.01-1.95 (m, 2H, cycloheptyl), 1.84-
1.71 (m, 4H, cycloheptyl), 1.65-1.54 (m, 6H, cycloheptyl).  
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N-[5-chloro-1-(4’-fluorobenzyl)-6-methyl-2-oxo-1,2-
dihydripyridin-3-yl]cycloheptanecarboxamide (E5) 
 
 
 
To a solution of N-(5-chloro-6-methyl-2-oxo-1,2-dihydripyridin-3-yl)-
cycloheptanecarboxamide 10 (0.109 g, 0.385 mmol) in DME (0.770 ml) and 
anhydrous DMF (0.190 ml) NaH 60% (0.0159 g, 0.397 mmol) was added 
portionwise at 0°C. 
LiBr (0.0669 g, 0.771 mmol) was added 10 minutes later. The reaction contents 
were stirred 15 minutes at room temperature, 4-fluorobenzyl chloride (0.0900 ml, 
0.743 mmol) was added dropwise and the reaction was stirred at 65°C overnight. 
The solvents were removed under reduced pressure. 
The reaction mixture was dissolved in CHCl3 and washed three times with brine. 
Then the organic phase was dried over anhydrous Na2SO4, filtered and evaporated 
under reduced pressure.  
The brown oil obtained was purified by flash chromatography on silica gel using, as 
eluent, petroleum ether/ethyl acetate (firstly 9:1 and then 8:2), to give a brown 
solid. 
The solid was crystallized in hexane to afford compound E5 as a white solid (0.0537 
g, 0.137 mmol). 
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Yield: 36% 
1H-NMR: (CDCl3) δ (ppm) 8.50 (s, 1H, H4 Py), 8.33 (bs, 1H, NH amide), 7.12-7.09 
(m, 2H, Ar), 7.04-7.00 (m, 2H, Ar), 5.37 (s, 2H, benzylic CH2), 2.46-2.42 (m, 1H, CH 
cycloheptyl), 2.38 (s, 3H, CH3), 2.00-1.94 (m, 2H, cycloheptyl), 1.81-1.71 (m, 4H, 
cycloheptyl), 1.61-1.48 (m, 6H, cycloheptyl). 
13C-NMR: (CDCl3) δ (ppm) 176.39, 161.01, 157.56, 134.35, 131.27, 131.24, 128.15, 
128.07, 123.48, 116.06, 115.84, 113.35, 48.50, 48.30, 31.47, 28.21, 26.44, 16.68. 
 
Melting point: 116-119°C 
Crystallization solvent: hexane  
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N-(5-fluoro-6-methyl-2-oxo-1,2-dihydripyridin-3-
yl)cycloheptanecarboxamide (12) 
 
 
 
To a suspension of N-(6-methyl-2-oxo-1,2-dihydripyridin-3-yl)-
cycloheptanecarboxamide 8 (0.700 g, 2.82 mmol) and acetonitrile, Selectfluor™ 
(1.199 g, 3.385 mmol) was added at room temperature. 
Reaction contents were refluxed at 89°C for 12 hours.  
After the completion of the reaction, the solvent was removed under reduced 
pressure. 
The mixture was diluted in ethyl acetate and washed three times with water. 
The organic phase was dried over anhydrous Na2SO4, filtered and evaporated 
under reduced pressure.  
The black solid obtained was purified by flash chromatography on silica gel using, 
as eluent, petroleum ether/ethyl acetate 5:5, to give compound 12 (0.0522 g, 
0.196 mmol) as a black solid. 
 
Yield: 7% 
1H-NMR: (CDCl3) δ (ppm) 8.48 (d, 1H, J=10.4 Hz, H4 Py), 8.16 (bs, 1H, NH amide), 
2.51-2.46 (m, 1H, CH cycloheptyl), 2.30 (d, 3H, J=2.8 Hz, CH3), 2.01-1.95 (m, 2H, 
cycloheptyl), 1.81-1.75 (m, 4H, cycloheptyl), 1.62-1.53 (m, 6H, cycloheptyl). 
 
Melting point: 92-98°C 
Crystallization solvent: hexane  
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N-[5-fluoro-1-(4’-fluorobenzyl)-6-methyl-2-oxo-1,2-
dihydripyridin-3-yl]cycloheptanecarboxamide (E6) and N-[5-
fluoro-2-((4’-fluorobenzyl)oxy)-6-methylpyridin-3-
yl]cycloheptanecarboxamide (E7) 
 
   
 
To a solution of N-(5-fluoro-6-methyl-2-oxo-1,2-dihydripyridin-3-yl)-
cycloheptanecarboxamide 12 (0.0563 g, 0.211 mmol) in DME (0.420 ml) and 
anhydrous DMF (0.100 ml) NaH 60% (0.00871 g, 0.218 mmol) was added 
portionwise at 0°C. 
LiBr (0.0367 g, 0.422 mmol) was added 10 minutes later. The reaction contents 
were stirred 15 minutes at room temperature, 4-fluorobenzyl chloride (0.0500 ml, 
0.408 mmol) was added dropwise and the reaction was stirred at 65°C overnight. 
The solvents were removed under reduced pressure. 
The reaction mixture was dissolved in CHCl3 and washed three times with brine. 
Then the organic phase was dried over anhydrous Na2SO4, filtered and evaporated 
under reduced pressure. 
The black oil obtained was purified by flash chromatography on silica gel using, as 
eluent, petroleum ether/ethyl acetate (firstly 9:1 and then 8:2), to give compound 
E6 as a brown oil and compound E7 as a white solid. 
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Compounds E6 and E7 were crystallized in distilled petroleum ether to afford a 
yellow oil (0.0191 g, 0.0510 mmol) and a white solid (0.0177 g, 0.0473 mmol) 
respectively. 
 
Yield (E6): 24% 
1H-NMR (E6): (CDCl3) δ (ppm) 8.43 (d, 1H, J=10.4 Hz, H4 Py), 8.40 (bs, 1H, NH 
amide), 7.14-7.11 (m, 2H, Ar), 7.04-7.00 (m, 2H, Ar), 5.32 (s, 2H, benzylic CH2), 
2.47-2.43 (m, 1H, CH cycloheptyl), 2.24 (d, 3H, J=3.2 Hz, CH3 Py), 2.05-1.95 (m, 2H, 
cycloheptyl), 1.80-1.73 (m, 4H, cycloheptyl), 1.59-1.57 (m, 6H, cycloheptyl). 
13C-NMR (E6): (CDCl3) δ (ppm) 176.54, 161.11, 156.74, 144.40, 131.49, 131.46, 
128.34, 128.26, 127.16, 123.26, 116.12, 115.91, 48.45, 47.78, 31.56, 28.28, 26.56, 
11.78. 
 
Crystallization solvent (E6): distilled petroleum ether 
 
 
Yield (E7): 22% 
1H-NMR (E7): (CDCl3) δ (ppm) 8.43 (d, 1H, J=10.4 Hz, H4 Py), 7.52 (bs, 1H, NH 
amide), 7.44-7.41 (m, 2H, Ar), 7.10-7.06 (m, 2H, Ar), 5.38 (s, 2H, benzylic CH2), 
2.40-2.38 (m, 1H, CH cycloheptyl), 2.35 (d, 3H, J=3.2 Hz, CH3 Py), 1.97-1.91 (m, 2H, 
cycloheptyl), 1.79-1.68 (m, 4H, cycloheptyl), 1.59-1.56 (m, 6H, cycloheptyl). 
13C-NMR (E7): (CDCl3) δ (ppm) 176.01, 161.64, 154.26, 151.83, 147.31, 133.11, 
130.51, 130.43, 121.20, 121.14, 115.63, 115.60, 67.79, 48.49, 31.74, 28.55, 28.50, 
26.58, 17.25. 
 
Melting point (E7): 90-103°C 
Crystallization solvent (E7): distilled petroleum ether  
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2-Hydroxy-4-methyl-3-aminopyridine (13) 
 
 
 
In a solution of commercial available 2-hydroxy-4-methyl-3-nitropyridine (1.00 g, 
6.49 mmol) in methanol, Pd/C (0.100 g) was added. 
The reaction contents underwent catalitic hydrogenation (three alternated cycles 
of vacuum and hydrogen); after that, the reaction contents were allowed to stir 
under hydrogen at room temperature overnight. 
The reaction mixture was filtered under vacuum using celite and the filtered was 
evaporated under reduced pressure to afford compound 15 (0.807 g, 6.50 mmol) 
as a brown solid. 
 
Yield: over 99% 
1H-NMR: (CDCl3) δ (ppm) 12.20 (bs, 1H, NH Py), 6.78 (d, J=6.8 Hz, 1H, H6 Py), 6.09 
(d, J=6.8 Hz, 1H, H5 Py), 4.03 (bs, 2H, NH2), 2.10 (s, 3H, CH3).  
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N-(4-methyl-2-oxo-1,2-dihydripyridin-3-
yl)cycloheptanecarboxamide (14) 
 
 
 
Cycloheptanecarboxylic acid (0.700 ml , 4.99 mmol) was dissolved in SOCl2 (2.60 
ml, 36.5 mmol) in a vial under nitrogen. The solution was stirred at 76°C for 3 
hours to allow the acyl chloride to generate. 
In the meantime, 2-hydroxy-4-methyl-3-aminopyridine 15 (0.310 g, 2.49 mmol) 
was dissolved in toluene (46.5 ml) and anhydrous DMF (6.20 ml) in a round bottom 
flask. After the dissolution, triethylamine (0.700 ml, 4.99 mmol) was added and the 
temperature was lowered to 0°C. 
After 3 hours, the solution in the vial was cooled to room temperature and then 
SOCl2 was removed under nitrogen. 
The acyl chloride formed was added dropwise, under nitrogen, to the solution in 
the the round bottom flask previously prepared and the reaction contents were 
allowed to stir at 32°C for 48 hours. 
The solvents were removed under reduced pressure. 
The reaction mixture was dissolved in CHCl3 and washed three times with water. 
Then the organic phase was dried over anhydrous Na2SO4, filtered and evaporated 
under reduced pressure.  
The brown solid obtained was purified by flash chromatography on silica gel using, 
as eluent, ethyl acetate with 2% acetic acid, to give compound 16 as an ocher solid. 
Compound 16 was triturated in hexane to afford a white solid (0.371 g, 1.49 
mmol). 
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Yield: 60% 
1H-NMR: (CDCl3) δ (ppm) 7.62 (bs, 1H, NH amide), 7.10 (d, 1H, J=6.4 Hz, H6 Py), 
6.26 (d, 1H, J=6.8 Hz, H5 Py), 2.53-2.48 (m, 1H, CH cycloheptyl), 2.16 (s, 3H, CH3), 
2.02-1.98 (m, 2H, cycloheptyl), 1.81-1.71 (m, 4H, cycloheptyl), 1.59-1.53 (m, 6H, 
cycloheptyl). 
 
Decomposition temperature: 150°C 
Crystallization solvent: hexane  
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N-[1-(4’-fluorobenzyl)-4-methyl-2-oxo-1,2-dihydripyridin-3-
yl]cycloheptanecarboxamide (F1) 
 
 
 
To a solution of N-(4-methyl-2-oxo-1,2-dihydripyridin-3-yl)-
cycloheptanecarboxamide 16 (0.0247 g, 0.0995 mmol) in anhydrous DMF (0.300 
ml), CsF (0.0454 g, 0.298 mmol) was added. 
The reaction contents were allowed to stir at room temperature for 1 hour; 4-
fluorobenzyl chloride (0.0400 ml, 0.298 mmol) was added dropwise and the 
reaction was stirred at 50°C overnight. 
The solvent was removed under reduced pressure. 
The reaction mixture was treated with ice-water and then extracted with CH2Cl2. 
The organic phase was dried over anhydrous Na2SO4, filtered and evaporated 
under reduced pressure.  
The brown oil obtained was purified by flash chromatography on silica gel using, as 
eluent, petroleum ether/ethyl acetate 5:5, to obtain compound F1 (0.0140 g, 
0.0393 mmol) as a white solid. 
 
Yield: 40% 
1H-NMR: (CDCl3) δ (ppm) 7.43 (bs, 1H, NH amide), 7.28-7.25 (m, 2H, Ar), 7.04 (d, 
1H, J=2.2 Hz, H6 Py), 7.03-7.00 (m, 2H, Ar), 6.10 (d, 1H, J=7.2 Hz, H5 Py), 5.07 (s, 
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2H, benzylic CH2), 2.52-2.47 (m, 1H, CH cycloheptyl), 2.12 (s, 3H, CH3), 2.06-2.00 
(m, 2H, cycloheptyl), 1.83-1.71 (m, 4H, cycloheptyl), 1.63-1.47 (m, 6H, cycloheptyl). 
13C-NMR: (CDCl3) δ (ppm) 176.22, 161.59, 159.72, 142.57, 132.22, 131.84, 130.23, 
130.14, 126.02, 116.23, 116.01, 110.38, 52.15, 48.20, 32.09, 28.43, 26.94, 20.00. 
 
Melting point: 160-165°C 
Crystallization solvent: hexane  
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N-(5-bromo-4-methyl-2-oxo-1,2-dihydripyridin-3-
yl)cycloheptanecarboxamide (15) 
 
 
 
N-(4-methyl-2-oxo-1,2-dihydripyridin-3-yl)-cycloheptanecarboxamide 16 (0.184 g, 
0.743 mmol) was dissolved in CHCl3 (1.20 ml) at room temperature. 
A solution of Br2 (0.0400 ml, 0.743 mmol) in CHCl3 (0.700 ml), previously prepared, 
was added dropwise to the first solution. The reaction contents were allowed to 
stir at 30°C for 24 hours. 
The reaction mixture was washed three times with a satured solution of Na2S2O3. 
Then the organic phase was dried over anhydrous Na2SO4, filtered and 
concentrated in vacuum to give compound 17 as a light yellow solid. 
Compound 17 was triturated in hexane to afford a white solid (0.207 g, 0.634 
mmol). 
 
Yield: 85% 
1H-NMR: (CDCl3) δ (ppm) 7.40 (bs, 1H, NH amide), 7.39 (s, 1H, H4 Py), 2.53-2.51 
(m, 1H, CH cycloheptyl), 2.20 (s, 3H, CH3), 2.05-2.01 (m, 2H, cycloheptyl), 1.83-1.75 
(m, 4H, cycloheptyl), 1.61-1.55 (m, 6H, cycloheptyl). 
 
Melting point: 217-219°C 
Crystallization solvent: hexane  
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N-[5-bromo-1-(4’-fluorobenzyl)-4-methyl-2-oxo-1,2-
dihydripyridin-3-yl]cycloheptanecarboxamide (F2) 
 
 
 
To a solution of N-(5-bromo-4-methyl-2-oxo-1,2-dihydripyridin-3-yl)-
cycloheptanecarboxamide 17 (0.154 g, 0.470 mmol) in anhydrous DMF (1.40 ml), 
CsF (0.214 g, 1.41 mmol) was added. 
The reaction contents were allowed to stir at room temperature for 1 hour; 4-
fluorobenzyl chloride (0.170 ml, 1.41 mmol) was added dropwise and the reaction 
was stirred at 50°C overnight. 
The solvent was removed under reduced pressure. 
The reaction mixture was treated with ice-water and then extracted with CH2Cl2. 
The organic phase was dried over anhydrous Na2SO4, filtered and evaporated 
under reduced pressure. 
The brown solid obtained was purified by flash chromatography on silica gel using, 
as eluent, petroleum ether/ethyl acetate 7:3, to obtain a yellow solid. 
The solid was crystallized in hexane to afford compound F2 as a light yellow solid 
(0.119 g, 0.272 mmol). 
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Yield: 58% 
1H-NMR: (CDCl3) δ (ppm) 7.48 (bs, 1H, NH amide), 7.33 (s, 1H, H4 Py), 7.30-7.27 
(m, 2H, Ar), 7.06-7.02 (m, 2H, Ar), 5.05 (s, 2H, benzylic CH2), 2.51-2.48 (m, 1H, CH 
cycloheptyl), 2.16 (s, 3H, CH3), 2.06-2.00 (m, 2H, cycloheptyl), 1.82-1.71 (m, 4H, 
cycloheptyl), 1.62-1.49 (m, 6H, cycloheptyl). 
13C-NMR: (CDCl3) δ (ppm) 176.23, 161.68, 158.56, 142.22, 132.24, 131.50, 130.39, 
130.30, 126.75, 116.37, 116.15, 104.22, 52.20, 48.08, 31.96, 28.37, 26.85, 20.81. 
 
Melting point: 167-170°C 
Crystallization solvent: hexane  
104 
 
N-[1-(4’-fluorobenzyl)-5-(4’-methoxyphenyl)-4-methyl-2-oxo-
1,2-dihydripyridin-3-yl]cycloheptanecarboxamide (F3) 
 
 
 
0.00165 g (0.00673 mmol) of Pd(OAc)2 were placed in a solution of 0.00883 g 
(0.0337 mmol) of PPh3 in toluene in a vial under nitrogen. 
After 10-15 minutes, p-methoxyphenylboronic acid (0.0696 g, 0.449 mmol), K2CO3 
(0.0465 g, 0.337 mmol) and N-[5-bromo-1-(4’-fluorobenzyl)-6-methyl-2-oxo-1,2-
dihydripyridin-3-yl]-cycloheptanecarboxamide F2 (0.0977 g, 0.224 mmol) were 
added to reaction. Reaction contents were allowed to stir at 110°C overnight. 
After the completion of the reaction, the mixture was filtered under vacuum using 
celite and then toluene was removed. Reaction mixture was extracted with 
CHCl3/water. Combined organic phase was dried over Na2SO4 and evaporated to 
afford a brown oil. 
The crude residue obtained was purified by flash chromatography on silica gel 
using, as eluent, petroleum ether/ethyl acetate 5:5 to give compound F3 as a 
yellow oil. 
Compound F3 was crystallized in hexane to afford a yellow oil (0.0748 g, 0.162 
mmol). 
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Yield: 72% 
1H-NMR: (CDCl3) δ (ppm) 7.54 (bs, 1H, NH amide), 7.32-7.28 (m, 2H, Ar), 7.17-7.15 
(m, 2H, Ar), 7.04-7.00 (m, 3H, Ar, H6 Py), 6.92-6.90 (m, 2H, Ar), 5.11 (s, 2H, benzylic 
CH2), 3.83 (s, 3H, OCH3), 2.54-2.50 (m, 1H, CH cycloheptyl), 2.12-2.01 (m, 2H, 
cycloheptyl), 1.98 (s, 3H, CH3), 1.83-1.74 (m, 4H, cycloheptyl), 1.59-1.53 (m, 6H, 
cycloheptyl). 
13C-NMR: (CDCl3) δ (ppm) 176.12, 161.33, 159.22, 158.66, 142.22, 135.86, 131.91, 
130.78, 130.08, 130.00, 129.02, 125.82, 123.43, 116.00, 115.78, 113.92, 55.39, 
51.97, 47.86, 31.85, 28.23, 26.67, 18.47. 
 
Crystallization solvent: hexane  
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N-[1-(4’-fluorobenzyl)-4-methyl-2-oxo-5-phenyl-1,2-
dihydripyridin-3-yl]cycloheptanecarboxamide (F4) 
 
 
 
0.00220 g (0.00901 mmol) of Pd(OAc)2 were placed in a solution of 0.0118 g 
(0.0450 mmol) of PPh3 in toluene in a vial under nitrogen. 
After 10-15 minutes, phenylboronic acid (0.0930 g, 0.600 mmol), K2CO3 (0.0622 g, 
0.450 mmol) and N-[5-bromo-1-(4’-fluorobenzyl)-4-methyl-2-oxo-1,2-
dihydripyridin-3-yl]-cycloheptanecarboxamide F2 (0.131 g, 0.300 mmol) were 
added to reaction. Reaction contents were allowed to stir at 110°C overnight. 
After the completion of the reaction, the mixture was filtered under vacuum using 
celite and then toluene was removed. Reaction mixture was extracted with 
CHCl3/water. Combined organic phase was dried over Na2SO4 and evaporated to 
afford a yellow oil. 
The crude residue obtained was purified by flash chromatography on silica gel 
using, as eluent, petroleum ether/ethyl acetate 6:4 to give compound F4 as a 
yellow oil. 
Compound F4 was crystallized in hexane to afford a white crystal solid (0.0589 g, 
0.136 mmol). 
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Yield: 45% 
1H-NMR: (CDCl3) δ (ppm) 7.54 (bs, 1H, NH amide), 7.52-7.24 (m, 7H, Ar), 7.06-7.01 
(m, 7H, Ar, H6 Py), 5.13 (s, 2H, benzylic CH2), 2.54 (m, 1H, CH cycloheptyl), 2.07-
2.02 (m, 2H, cycloheptyl), 2.00 (s, 3H, CH3), 1.82-1.75 (m, 4H, cycloheptyl), 1.60-
1.29 (m, 6H, cycloheptyl). 
13C-NMR: (CDCl3) δ (ppm) 176.05, 161.35, 158.72, 141.85, 136.78, 131.94, 131.91, 
131.00, 130.08, 130.00, 129.67, 128.52, 127.72, 126.02, 123.77, 115.99, 51.98, 
47.81, 31.85, 28.25, 26.67, 18.41. 
 
Melting point: 143-146°C 
Crystallization solvent: hexane  
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N-(5-chloro-4-methyl-2-oxo-1,2-dihydripyridin-3-
yl)cycloheptanecarboxamide (16) 
 
 
 
In a suspension of N-(4-methyl-2-oxo-1,2-dihydripyridin-3-yl)-
cycloheptanecarboxamide 16 (0.189 g, 0.762 mmol) and acetonitrile, N-
chlorosuccinimide (0.102 g, 0.762 mmol) was added. Reaction contents were 
refluxed at 89°C overnight. After the completion of the reaction, the solvent was 
removed under reduced pressure. 
The mixture was quenched with water and extracted with ethyl acetate. 
The organic phase was dried over anhydrous Na2SO4, filtered and concentrated 
under reduced pressure. The yellow solid obtained was purified by flash 
chromatography on silica gel using, as eluent, ethyl acetate/petroleum ether 7:3 
with 1% acetic acid, to give compound 18 as a yellow solid. 
Compound 18 was triturated in hexane to afford a white solid (0.104 g, 0.368 
mmol). 
 
Yield: 48% 
1H-NMR: (CDCl3) δ (ppm) 8.73 (bs, 1H, NH Py), 7.52 (s, 1H, H6 Py), 7.29 (bs, 1H, NH 
amide), 2.54 (m, 1H, CH cycloheptyl), 2.18 (s, 3H, CH3), 2.04-2.01 (m, 2H, 
cycloheptyl), 1.83-1.73 (m, 4H, cycloheptyl), 1.66-1.49 (m, 6H, cycloheptyl). 
 
Decomposition temperature: 200°C 
Crystallization solvent: hexane  
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N-[5-chloro-1-(4’-fluorobenzyl)-4-methyl-2-oxo-1,2-
dihydripyridin-3-yl]cycloheptanecarboxamide (F5) 
 
 
 
To a solution of N-(5-chloro-4-methyl-2-oxo-1,2-dihydripyridin-3-yl)-
cycloheptanecarboxamide 18 (0.104 g, 0.368 mmol) in anhydrous DMF (1.10 ml), 
CsF (0.168 g, 1.10 mmol) was added. 
The reaction contents were allowed to stir at room temperature for 1 hour; 4-
fluorobenzyl chloride (0.132 ml, 1.10 mmol) was added dropwise and the reaction 
was stirred at 50°C overnight. 
The solvent was removed under reduced pressure. 
The reaction mixture was treated with ice-water and then extracted with CH2Cl2. 
The organic phase was dried over anhydrous Na2SO4, filtered and evaporated 
under reduced pressure. 
The brown oil obtained was purified by flash chromatography on silica gel using, as 
eluent, petroleum ether/ethyl acetate (firstly 7:3 and then 5:5), to obtain 
compound F5 as a light yellow solid. 
Compound F5 was triturated in hexane to afford a white solid (0.0559 g, 0.143 
mmol). 
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Yield: 39% 
1H-NMR: (CDCl3) δ (ppm) 7.49 (bs, 1H, NH amide), 7.31-7.28 (m, 2H, Ar), 7.22 (s, 
1H, H6 Py), 7.07-7.03 (m, 2H, Ar), 5.07 (s, 2H, benzylic CH2), 2.52-2.49 (m, 1H, CH 
cycloheptyl), 2.15 (s, 3H, CH3), 2.06-2.00 (m, 2H, cycloheptyl), 1.83-1.72 (m, 4H, 
cycloheptyl), 1.62-1.50 (m, 6H, cycloheptyl). 
13C-NMR: (CDCl3) δ (ppm) 176.04, 161.47, 158.21, 141.14, 131.32, 131.28, 130.19, 
130.11, 129.60, 126.61, 116.13, 115.92, 115.73, 51.99, 47.81, 31.75, 31.64, 28.26, 
28.17, 26.64, 17.83. 
 
Melting point: 197-199°C 
Crystallization solvent: hexane  
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N-(5-fluoro-4-methyl-2-oxo-1,2-dihydripyridin-3-
yl)cycloheptanecarboxamide (17) 
 
 
 
To a suspension of N-(4-methyl-2-oxo-1,2-dihydripyridin-3-
yl)cycloheptanecarboxamide 14 (0.370 g, 1.49 mmol) and acetonitrile, Selectfluor™ 
(0.634 g, 1.79 mmol) was added at room temperature. 
Reaction contents were refluxed at 89°C for 12 hours.  
After the completion of the reaction, the solvent was removed under reduced 
pressure. 
The mixture was diluted in ethyl acetate and washed three times with water. 
The organic phase was dried over anhydrous Na2SO4, filtered and evaporated 
under reduced pressure.  
The brown solid obtained was purified by flash chromatography on silica gel using, 
as eluent, petroleum ether/ethyl acetate 6:4, to give compound 17 (0.0280 g, 
0.105 mmol) as a yellow solid. 
 
Yield: 7% 
1H-NMR: (CDCl3) δ (ppm) 8.49 (bs, 1H, NH amide), 7.72 (s, 1H, H4 Py), 2.57 (m, 1H, 
CH cycloheptyl), 2.04 (s, 3H, CH3), 2.00 (m, 2H, cycloheptyl), 1.80-1.78 (m, 4H, 
cycloheptyl), 1.62-1.52 (m, 6H, cycloheptyl).  
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